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ABSTRACT 
Background: Pain is a major clinical problem during childbirth and postoperatively after 
caesarean section (CS) and hysterectomy. There are several reasons why pain should be 
minimized; pain is indeed a negative sensation, it affects the birth-experience and the entire 
post-operative recovery, with reduced wellbeing and extended time in hospital. Inadequately 
treated pain is a risk factor for persistent pain. Multimodal pain treatment, combining 
different analgesics with different mode of action to reach additive or synergistic analgesic 
effect; thereby gain effective pain management but a lower incident of side effects has 
become praxis. Adding small amounts of morphine to local anaesthetic for spinal anaesthesia 
is an attractive combination improving intraoperative anaesthesia and postoperative 
analgesia. The use of intrathecal morphine (ITM) is however associated to side effects, where 
respiratory depression is the most feared adverse effect, which restricted its use. Obesity per 
se is associated with risk for respiratory complications e.g. sleep apnoea and hypoventilation. 
Thus obesity, ITM and pregnancy may act additive increasing risk for respiratory depression 
and the risk for respiratory depression has been seen more commonly in obese mothers after 
caesarean section CS. The aim of this thesis was to study morphine as adjunct to bupivacaine 
in neuroaxial anaesthesia in different perspectives; ITM used in spinal labour analgesia, ITM 
used in spinal for post hysterectomy pain, the use of neuroaxial administered morphine in 
Sweden, the role of polygraphic registration in obese mothers after CS in spinal anaesthesia 
including ITM and finally the use of general and regional anaesthesia ITM in emergent CS.  
Methods and Main Results: Study I and II are randomized double-blinded placebo-
controlled trials investigating the effects of different doses of morphine added to local 
anaesthetic intrathecally.  
In Study I we compared the addition of morphine 50, 100 µg or saline to intrathecal 
bupivacaine (1.25 mg) and sufentanil (5 µg) to evaluate the impact on duration of labour 
analgesia as part of a combined spinal-epidural technique in 90 nulliparous labouring women. 
Duration of analgesia was defined as the time from intrathecal injection to the return of pain 
VAS >4. No significant differences were seen in onset or duration of analgesia, obstetric and 
neonatal outcome or side effects, between the groups.  
In Study II ASA I-II women (n=144) scheduled for abdominal hysterectomy in combined 
general and spinal anaesthesia were randomised to spinal anaesthesia with 12 mg of 
hyperbaric bupivacaine combined with 100, 200, and 300 µg morphine or saline. Primary 
outcome was 24 h used nurse administered and patient controlled analgesia (PCA)-morphine. 
ITM reduced accumulated 24 h post-operative morphine consumption. Morphine 100 µg 
reduced morphine consumption significantly vs. placebo at 0–6 h, 6–12 h, and for the entire 
0–24 h after operation. Morphine 200 µg further reduced morphine consumption significantly 
vs. morphine 100 µg at 0–6 h and for the entire 0–24 h after operation. Morphine 300 µg did 
not further reduce the morphine consumption. Emesis was experienced similar in all groups, 
and pruritus occurred only in the morphine groups. No serious side effects were observed.  
In Study III we investigated the use of intrathecal and epidural opioids in mainly CS, and 
hysterectomies in Sweden by a questionnaire to anaesthetists in charge of obstetric 
anaesthesia units.  We had 68% of units responding and found in CS spinal anaesthesia, 
20/32 units use ITM, the most common dose was 100 µg (17/21). Addition of intrathecal 
fentanyl (10-20 µg) or sufentanil (2.5-10 µg), was used by 21 and 9 units respectively. In CS 
epidural anaesthesia 12/32 clinics used epidural morphine, the majority of units used a 2 mg 
dose while use of fentanyl (50-100 µg) or sufentanil (5-25 µg) was more common, in 10 and 
15 units respectively. For hysterectomy ITM was used by 20/32 units (80-200 µg), the 
majority used 200 µg dose (9/32). Risk of respiratory depression and difficult to monitor 
postoperatively was the main reason for withholding intrathecal opioids in 7/12 units.  
Study IV is a prospective observational study to explore the occurrence of sleep disorder 
breathing in obese mothers and use of portable sleep apnoea polygraphy for respiratory 
monitoring the first night after CS with bupivacaine/morphine/fentanyl spinal anaesthesia, 
assessing the occurrence of apnoea/hypopnea index (AHI) and oxygen desaturation index 
(ODI). Among the 20 mothers that completed polygraphic registration: 11 had normal 
apnoea-hypopnea index (AHI <5) 7 had mild; AHI ≥5 and <15; and 2 had moderate; AHI 
≥15 (15.3 and 18.2) but no one had severe obstructive sleep apnoea, OSA (AHI ≥30). Those 
mothers with moderate OSA did not show high ODI or signs of hypercapnia on 
transcutaneous CO2 registration. The ODI was on average 4.4, eight mothers had an ODI >5. 
Mean saturation was 94% (91-96%), and four mothers had mean saturation between 90-94%, 
but none had a mean SpO2 <90%. None of the mothers showed clinical signs or symptoms of 
severe respiratory depression, registered by routine clinical monitoring.  
Study V is a retrospective chart review of emergency CS (ECS) at Danderyd Hospital 
between January and October 2016 with the aim to assess the decision to delivery interval 
(DDI) and the impact of chosen anaesthetic technique, general anaesthesia (GA), spinal 
anaesthesia (SA) with opioid supplementation, or “top-up” of labour epidural analgesia 
(tEDA) with local anaesthesia and fentanyl mixture, and work shift for ECS at Danderyd 
Hospital, Sweden. In total, 135 ECS were analysed: 92% were delivered within 30 minutes. 
Mean DDI for all CS was 17.3 ± 8.1 minutes. With GA DDI was shortened by 10 and 13 
minutes compared to SA and tEDA (p<0.0005). DDI for SA and tEDA was similar. No 
difference in DDI was seen regarding time of day or weekday. Apgar <7 at 5 min. was found 
more commonly in ECS having GA (11/64) vs. SA (2/30) and tEDA (1/41)(p<0.05). 
Conclusions: Low dose ITM has an important role mainly in a fast track concept to minimize 
systemic opioid consumption and still optimize postoperative analgesia in elective and 
emergent CS in recommended dose of 100 µg and hysterectomy 200 µg. If spinal labour 
analgesia is chosen addition of ITM doses 100 µg or less seems of no value to prolong the 
duration. ITM is widely used in Sweden in mainly CS and hysterectomy, although still 
restricted in some units due to fear of respiratory depression and/or difficulties monitoring 
postoperatively. Respiratory monitoring with polygraphy in obese mothers after CS ITM 
anaesthesia did not reveal severe sleep disorder breathing and seems to be of limited value in 
the postoperative period after CS performed in spinal anaesthesia including morphine. We 
found 92% of ECS, were delivered within 30 min. and DDI was shortened with GA by 10 
and 13 minutes compared to SA and tEDA but with no difference between SA and tEDA.  
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1 INTRODUCTION AND RATIONALE 
Pain during labour and postoperative after CS and hysterectomy is not only unpleasant and 
causes reduced wellbeing but has also a direct impact on complications, recovery, time in 
hospital and development into persisting pain (1-3). The mother might choose an elective CS 
next time if the first vaginal birth experience was painful. Thus apart from a human 
perspective there are also economic incentives to minimize pain during these procedures.  
There are several ways to reduce pain. During vaginal birth, neuroaxial analgesia is proven to 
give the most effective pain relief (4). Systemic opioids are shown to have limited effect on 
pain during labour but in neuraxial route opioids are proven effective (5-7). There is 
increased request for pain relief during labour. Single shot spinal analgesia is an alternative to 
epidural analgesia during labour, easier to administer and with faster onset of pain relief but 
with a restricted duration as limitation.  
The majority of CS’s are performed in single shot spinal anaesthesia. Addition of a low dose 
ITM is proven to create good, long lasting pain relief and is regarded as golden standard. Still 
it came to our knowledge that several units chose not to use addition of ITM in spinal 
anaesthesia for CS.  
In abdominal hysterectomy spinal anaesthesia with sole bupivacaine and sole ITM has shown 
to reduce the postoperative morphine consumption vs. general anaesthesia in order to 
enhance fast recovery (8, 9). Several doses of ITM have been used in this setting but to us 
there were no known studies comparing effects of the different doses of ITM when added to 
bupivacaine.  
Administration of morphine, no regard to whether by intravenous, intramuscular or neuraxial 
route, may result in side effects such as nausea and vomiting, pruritus, sedation and, although 
rare, the most feared side effect, respiratory depression. Respiratory depression may be 
delayed, thus how and for how long time patients should be monitored, after receiving 
neuroaxial morphine, is discussed. The opioid, the dose, and route of administration do 
impact the risk of respiratory depression and the benefit vs. risk should be thoroughly 
addressed. There are also other factors that may increase risk of side effects. Obese mothers 
have been found to develop respiratory depression to a greater extent than mothers of normal 
weight after caesarean section in spinal anaesthesia including morphine (10).  
The rationale for this thesis was to achieve better knowledge about effects of different low 
doses of ITM in clinical use during labour and perioperative and postoperatively, whether 
addition of a low dose of ITM would prolong duration of single spinal labour analgesia and 
what dose of ITM would decrease postoperative intravenous patient controlled morphine 
analgesia without increasing side effects. We were interested in to what extent ITM is 
routinely used in Sweden and what is limiting its use. We aimed at observing respiratory 
pattern postoperative after CS performed in spinal anaesthesia in the obese cohort and sort 
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out whether polygraphy would be of use to identify respiratory depression in this setting. We 
studied the role of neuroaxial anaesthesia including ITM, in emergency category 1 and 2 CS.  
Better knowledge about the effects of ITM doses, routine use and the reasons why some 
choose not to use ITM, role of respiratory depression after ITM could contribute to improve 
prevention and treatment of pain in labour, CS and hysterectomy. 
  3 
2 BACKGROUND 
2.1 PAIN 
The International Association for the study of Pain IASP, defined pain 1979 as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage”. IASP further states “as pain always is 
unpleasant it is therefore also an emotional experience. Pain is always subjective. Each 
individual learns the application of the word through experiences related to injury in early 
life” (11) 
Pain perception begins in the periphery with stimulation of sensory nerves, further conducted 
via a complex series of nociceptive transmissions, resulting in generation of action potentials 
within the spinal cord and synaptic transmission to other supra spinal sites (12). 
Mechanical, chemical and thermal stimuli activate sensory (nociceptor) neurons causing 
nociceptive pain, that signals intensity, localisation and duration of the stimulus and pain is 
reduced, disappear, when the stimulus is removed (13). When there is a surgical wound there 
will be inflammatory pain ongoing until the wound has healed. Peripheral sensitisation is 
caused by tissue injury and inflammation with release of sensitising inflammatory mediators 
causing lowered threshold of the innervating sensory neurons in the damaged tissue (13). 
Central sensitisation is caused by enhanced excitability of CNS neurons and results in 
intensified responses and spread sensitivity to normal sensory inputs. 
If nerves are injured or sensory transmitting systems in the brain and spinal cord, this will 
cause neuropatic pain. Neuropatic pain is characterized by sensory loss in the area innervated 
by the nerve, but some individuals also develop spontaneous pain, hypersensitivity and 
dysaesthesia, triggered by slight stimuli like light touch. 
The patient senses pain through the afferent pain pathway, which can be altered by various 
pharmacologic agents. Somatic pain-transmitting A-delta nerve fibres, enter the spinal cord 
through the dorsal roots, and terminate in a dense network of synapses, in the ipsilateral 
laminae I and II of the dorsal horn. There is minimal rostro-caudal extension of those fibers. 
Visceral C-fibers terminate in a loose network of synapses in the dorsal and ventral horn and 
cross over to the contralateral side with extensive rostro-caudal extension of fibers. This 
underlies the more diffuse localization of visceral pain versus somatic pain. 
Pain experienced in labour and postoperatively after CS and hysterectomy is influenced by 
multiple physiological and psychosocial factors. 
2.1.1 Labour Pain  
Historically, and sometimes still, labour pain has been described as minor but by a 
questionnaire in 1984 Melzack found labour pain to be rated as painful as a digit amputation 
performed without anaesthesia, by nulliparous women without childbirth training (14). 
Nulliparous women with childbirth training scored lower pain but still high level of pain (14). 
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Pain experienced during first stage of labour is primary caused by cervical distension and 
transduced by afferents in the cervix and lower uterine segment rather than the uterine body. 
The visceral utero-cervical C-afferents enter the spinal cord in the region 10th,11th and 12th 
thoracic and 1st Lumbar spinal segments and terminate in the deep dorsal and ventral horn 
and cross the midline to the contralateral side. The pain is diffusely localized. As labour 
progresses the pain usually increases and pain during second stage of labour is transmitted by 
the same afferents activated during first stage with addition of somatic afferents that innervate 
the cervix vaginal surface, vagina and perineum, via the pudendal nerve to the 2nd, 3rd and 4th 
sacral spinal segments. The pain is more localized and reflects distension, ischemia and injury 
in the innervated area. 
Apart from being unpleasant, pain during labour may influence labour and obstetric course. 
Increased secretion of epinephrine may cause beta-adrenergic tocolysis meaning inhibition of 
uterine contractions. Severe pain and fear may lead to the woman deciding to have an elective 
caesarean for the current or the following pregnancy. Labour pain may also continue as 
persisting pain when it is suboptimal handled (15).  
2.1.2 Postoperative pain  
There are a lot of different factors involved in the severity of experienced early postoperative 
pain, such as psychological, social and somatic factors together with operational technical 
and handling of pre-, peri-, and postoperative pain and anxiety. Women are found to suffer 
from higher postoperative pain vs. men (13). 
Surgical pain is due to inflammation from tissue trauma or direct nerve injury (i.e., nerve 
transaction, stretching, or compression). Pain impulses are transmitted by A-delta and C-
fibers and result in an experience of combination of localized somatic pain and more diffuse 
and dull visceral pain. Pain after CS and abdominal hysterectomy is depending on surgical 
technique, and approach for abdominal access, Phannenstiel or midline. Pain is mediated 
from the entire surgical field, abdominal wall, peritoneum and uterine fixation apparatus. It 
enters spinal cord on a wide range of segments. The dorsal roots affected during open 
hysterectomy are thus larger in numbers as compared to labour pain. Hysterectomy can also 
be performed with laparoscopy technique usually with reduced postoperative pain due to less 
traumatic surgery.  
 
2.2 HANDLING OF PAIN 
Pain can be managed by a variety of drugs and techniques. Oral administration of pain-
medication such as paracetamol and NSAIDs e.g. ibuprofen is commonly available as over 
the counter analgesics. The combination of paracetamol and NSAID is also the first step on 
the escalating pain management staircase of multimodal pain management of postoperative 
pain. The concept of multi-modal or balanced analgesia combining analgesics with different 
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modes of action and side effects all aiming at minimizing the opioid need and opioid related 
side effects, morphine sparing analgesia has become standard of care (16).  
Opioid analgesics e.g. morphine, administrated orally or intravenously, are mainly used for 
intense pain. Patient Controlled Analgesia, PCA morphine is common practise and often next 
step on the pain-staircase. 
Local anaesthesia infiltrated or in a regional block e.g. Transversus Abdominis Plane (TAP) 
block can contribute to extra pain relief and is recommended to decrease systemic opioids 
(17).  
Spinal or epidural local anaesthesia, often with morphine/morphine analogues added, thus 
providing both intra- and postoperative analgesia, is an attractive alternative in order to 
provide good pain relief with low incidence of side effects.  
Ketamine, gabapentin or pregabalin are other drugs that have become popular to minimize 
the extent of neuropathic component in postoperative pain.  
 
2.3 PERSISTENT PAIN  
Postsurgical persistent pain resembles neuropathic pain and is probably often caused by 
damaged nerves, but there are also patients suffering from continuous inflammatory pain. 
Studies confirm that previous pain and the intensity of experienced early postoperative pain 
correlates with the risk of developing persistent postsurgical pain (13). 
There are studies documenting that 4-10 % of vaginal births are followed by chronic pain 
problems (15). Eisenach et al. found 1 of 13 women suffering from severe acute pain after 
vaginal delivery, and that acute postpartum pain was a large independent risk factor for 
persistent pain (18).  
Chronic pain may emerge after caesarean delivery and is influenced by the extent of acute 
post-operative pain (2). Eisenach et al. found 1 of 5 women suffering from acute post-
operative pain after CS and in line with postpartum pain after vaginal delivery, acute post-
operative pain after CS was a large risk factor for persistent pain (18). Incidence of persistent 
pain 8 weeks post-partum was 9.8% with no significant difference regarding mode of 
delivery, vaginal versus caesarean delivery (18). 
One year after hysterectomy persistent pain was found in an incidence of 32% (19). Chronic 
pain was defined by Brandsburg et al. as ”having pelvic pain within the last 3 months”, in the 
questionnaire sent to 1299 patients, and answered by 90.3 %. 13.7% had pain more than 2 
days a week. In a follow up review the authors found chronic pain problem is reported by 
4.7–31.9% after hysterectomy in 11 identified studies (19). More pronounced postoperative 
pain is a risk factor for persisting pain. Spinal anaesthesia during hysterectomy was 
associated with lower frequency of chronic pain (3).  
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2.4 OPIOIDS FOR NEUROAXIAL USE 
The most common opioids used as adjuncts in spinal and epidural analgesia today are the 
naturally occurring, by poppy plant synthesized morphine, semisynthetic diamorphine (not in 
use in Scandinavia) and synthetic phenylpiperidines like fentanyl and sufentanil.  
Small doses of intrathecal morphine (ITM) was described 40 years ago to produce profound 
analgesia with no effect on motor function, while similar doses given systemically had 
negligible effect, showing a direct spinal mechanism of ITM (20).   
Opioids bind to and activate opioid receptors that subsequently inhibit calcium channels and 
ascending nociceptive stimuli from the dorsal horn of the spinal cord.  
Morphine, fentanyl and sufentanil in low doses bind to the µ-opioid receptor and mediate 
analgesia but also side effects like sedation, decreased gastrointestinal transition and 
respiratory depression (12).  
2.4.1 Pharmacology 
There are important pharmacological differences between opioids, like lipid- and hydro-
solubility (=lipo- and hydro-philicity), molecular weight, pKa and protein binding. These 
biochemical properties have impact on kinetics, time to onset and offset of action. There is 
also different potency between the opioids. The differences in kinetics and potency have 
major influence on the clinical analgesic properties. Morphine is hydrophilic with low lipid 
solubility, 1.4 expressed in octanol-water partition coefficient to compare with high lipid 
solubility with fentanyl, 816, and further high with sufentanil, 1727. More rapid onset of 
analgesia is seen with higher lipid solubility. When an opioid is administered in the epidural 
space it first diffuses through the dura and arachnoid membranes, via the cerebrospinal fluid 
(CSF) and pia membrane, to the spinal cord and further through the white and grey matter to 
finally reach the dorsal horn with the µ-receptors which is the site of action. Uptake into 
epidural fat or systemic circulation is competing processes that limit the diffusion to the 
spinal cord. Lower pKa, and lower percent of protein binding results in a larger share of 
uncharged form of the opioid at body pH of 7.4, that penetrates the dura more easily. The 
pKa and protein binding percent for morphine, fentanyl and sufentanil is 7.9/ 35, 8.4/ 84 and 
8.0/ 93 respectively. Hydrophilic opioids like morphine move rapidly within CSF and do not 
return to the epidural space, such as lipophilic opioids that redistribute to a large extent and 
are absorbed systemically from the epidural fat.  
2.4.2 Doses  
In 1979 Samii et al. reported about ten patients in pain that were given 20 mg morphine 
intrathecally with onset of analgesia at 26 ± 4 minutes and duration of analgesia for 27 ± 2 h, 
proposing a direct spinal opioid effect (21). The 20 mg single shot morphine dose is high also 
for intravenous administration and the intrathecal administration of one single direct injection 
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of this dose is huge, it is a dose that is 100 – 400 times greater than the doses used 
intrathecally commonly today illustrating a large therapeutic interval. 
The same year Wang et al. published a study where eight patients with severe back pain 
secondary to malignancies received ITM, 0.5 – 1.0 mg, and achieved complete pain relief 
during 12 to 24 hours. Increasing the morphine dose from 0.5 to 1.0 mg did not prolong the 
relief of pain proportionately. The writers propose the technique may be used for obstetric 
analgesia or postoperative pain (22). 
Today intrathecal opioids are widely used for analgesia. Earlier studies used mostly ITM as a 
sole analgesic in greater doses, while later trials use a combination of local anaesthetic, 
smaller doses ITM and/ or a lipid soluble opioid in order to get sufficient analgesia and still 
minimize side effects especially since some of the side effects are potentially severe. In 
obstetric and gynaecological anaesthesia low dose combined mixture has been shown to be 
effective in labour analgesia and as postoperative analgesia in caesarean section and 
abdominal hysterectomy. Tables with listed studies of intrathecal anaesthesia for labour and 
post abdominal hysterectomy pain show the development and different results (Table 16 and 
17). 
2.4.3 Side effects 
Large doses of ITM is associated with a high incidence of side effects (6). Pruritus is the most 
common side effect and is described as dose related (6). Nausea and vomiting occur 
commonly postoperatively and during labour and it is therefore difficult to determine to what 
extent nausea and vomiting is a direct side effect of neuroaxial analgesia. Ondansetron is 
commonly administrated as prophylaxis and as treatment of postoperative nausea and 5HT3 
antagonists have also been used to treat pruritus and shown to reduce the incidence of severe 
pruritus (23).  
2.4.3.1 Respiratory depression  
The most feared side effect of opioids is sedation and respiratory depression that can be seen 
regardless of route of administration. Early respiratory depression is observed when lipophilic 
opioids are administered intrathecally or epidurally, with a short time frame as the 
elimination rate is similar with the intravenous rout. However hydrophilic opioids like 
morphine stay in CSF for several hours, with rostral migration and absorption into respiratory 
centers in the brainstem, and can cause late respiratory depression up to 12 h after 
administration. American Society of Anaesthesiologists recommend monitoring of 
ventilation, oxygenation and level of consciousness in patients receiving opioids and for 
morphine to be performed hourly for 12 h after administration, and every second h for the 
next 12 h. The low but serious risk of late respiratory depression must be acknowledged 
whenever intrathecal or epidural opiates are administered. There are risk factors for 
respiratory depression to identify and consider such as advanced age, cardiopulmonary 
disease, operation, obesity and obstructive sleep apnoea. The incidence of respiratory 
depression in obstetric patients after neuroaxial morphine is 0-0.9% (24). Aboulish et al. 
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found 8/856 cases of respiratory depression, defined as <10 breath/min or desaturation < 85% 
on room air, in a study on CS in spinal anaesthesia including 200 µg ITM (10). All 8 mothers 
were obese (105 ± 2.1 kg) and the respiratory depression during sleep was not reversed by 
treatment with naloxone (10). Kato et al. retrospectively reviewed CS having 150 µg ITM 
and found 6/1915 patients experiencing bradypnea, respiratory rate (RR) ≤ 10 breaths/min; 
one obese with BMI 35, having OSA, with the same respiratory pattern during following 
nights (25). To our knowledge there are no studies of postoperative respiratory compromise 
conducted, explicitly assessing risk in obese mothers after CS. In a retrospective study of 
5036 mothers having CS in spinal or epidural anaesthesia including morphine, 63% of the 
patients were obese (26). Crowgey et al. defined respiratory compromise with need for 
naloxone as oxygen saturation <90%, RR≤8 breaths / minute or value of <-2 on Richmond 
Agitation Sedation Scale and found no such event (26). There are multiple definitions used in 
studies assessing risk of respiratory impairment of opioids (27). There is a lack of clear 
definition of what a significant clinically respiratory impact caused by ITM is, and what kind 
of monitoring that is best catching any clinically respiratory impairment of importance (28). 
In a review regarding risk, prevention and monitoring of respiratory depression caused by 
spinal/ epidural morphine use in obstetric anaesthesia, Carvalho supports monitoring of 
sedation and RR up to 24 hours after neuroaxial morphine injection in low risk mothers, 
complemented with oxygen saturation in high risk cohort like obese mothers (24). 
2.4.4 Labour analgesia 
There are several different ways to handle labour pain but epidural and spinal analgesia are 
the most effective methods (29). Continuous epidural analgesia is today the most common 
neuroaxial method, sometimes initiated with a spinal as combined spinal epidural analgesia. 
However this thesis focus mainly on use of ITM and thus pharmacologic aspects in epidural 
labour analgesia will not be further reviewed. Single spinal labour analgesia is indicated 
when analgesia is required shortly before vaginal delivery. Advantages are that it is a 
technically simple and fast method to reach rapid onset of analgesia including sacral 
analgesia with low drug doses. The limited duration is the main disadvantage.  
Historically neuroaxial labour analgesia started with injection of 0.01g Cocaine in single 
spinal in 1900 by Kreis, who stated: “the impression gained from the medullary narcosis in 
parturients is remarkable. Loss of sensation to pain with maintained mobility and unclouded 
sensorium is most unusual.”(30). Stone, also using cocaine in single spinal for labour 
analgesia, concluded in 1901: “For, with but little practice, any physician can become 
competent to perform the lumbar puncture”(31). Sole morphine in single spinal was used 
early in obstetric neuroaxial analgesia. Table 16 shows studies of ITM for labour analgesia. 
Scott et al. published in 1980 a study of 12 patients in labour, who received 1.5 mg ITM as a 
sole agent, and observed abolished pain during first stage of labour and abolished pain during 
second stage for four patients and reduced for three (32). Though the used morphine dose was 
high by our norm, the side effects including itching of the face, nausea and vomiting, and 
frontal headache, were described as mild and simply treated (32). Baraka et al. compared in 
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1981 1 mg with 2 mg of ITM in labouring women and found onset to be between 15 to 60 
min. and duration between 8 to 11 hours but described in contrast to Scott et al. that the 
majority of patients had somnolence, nausea, vomiting and pruritus (33). In 2001 Yeh et al. 
used a far lower morphine dose in labouring women with a combination of intrathecal 
bupivacaine 2.5 mg and fentanyl 25 µg with or without 150 µg morphine, and found the 
duration significantly prolonged in morphine group, but still adverse effects did not 
significantly differ between groups (34).  
2.4.5 Caesarean section 
In spinals for caesarean section a combination of ITM and local analgesic was introduced 
early. Abboud et al. showed in 1988 that 100 – 250 µg morphine combined with bupivacaine 
0.75% was effective in reducing postoperative pain after caesarean section with minimal or 
no side effects (35). Several trials performed conclude intrathecal morphine 75-100 µg 
combined with bupivacaine 0.5 % 10-15 mg for CS is sufficient in reducing post caesarean 
section pain (36-38). Combining hyperbaric bupivacaine with low dose of a lipophilic opioid, 
with rapid onset to enhance intraoperative and first postoperative hours analgesia, and a 
hydrophilic opioid in order to prolong the duration of postoperative pain relief in a 
multimodal analgesia approach including paracetamol and NSAID is often used and 
recommended for CS spinal anaesthesia (39-41).  
2.4.6 Hysterectomy 
In abdominal hysterectomy Sarma et al. tested in 1993 three different doses of intrathecal 
morphine: 100, 300 and 500 µg given after the operation and used no local anaesthetic and 
found better analgesia in all morphine groups, best in 300 and 500 µg but no better analgesia 
in 500 group compared with 300 (9). Nausea and vomiting occurred most in 0-group, and 
least frequently in 300-group. Pruritus was seen only in morphine groups, most in 500-group 
(9). 
In 1996 Wang et al. compared general inhalational with spinal anaesthesia including sole 
bupivacaine 15 mg for low abdominal women surgery and found spinal anaesthesia providing 
both perioperative anaesthesia and less post-operative pain first 24 h (8).  
 
2.5 OBSTRUCTIVE SLEEP APNOEA 
Obstructive sleep apnoea is a state when upper airway collapse and obstruction during sleep 
occur with usually snoring, oxygen desaturation and arousal from sleep. Screening for 
obstructive sleep apnoea is commonly performed with portable at-home polygraphy 
monitoring equipment, with collection of information about gas flow, saturation and thoracic 
and abdominal movements. Using defined algorithms this information is then transformed 
into indices: apnoea-hypopnea index (AHI) and oxygen desaturation index (ODI).  
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Apnoea: America Academy of Sleep Medicine defines apnoea as a drop in the polygraphy 
peak signal excursion by ≥90% of pre-event baseline airflow signal with duration ≥10 
seconds (42).  
Hypopnea: is classified as a drop in peak signal excursion by ≥30% of pre-event baseline 
airflow signal lasting ≥10 seconds in association with either ≥ 3% arterial oxygen 
desaturation or an arousal (42). 
The apnoea/hypopnea index (AHI): is the number of apnoea/hypopnea events registered 
per hour, and are graded into three categories of Obstructive Sleep Apnoea (OSA):  
Mild OSA: AHI of ≥5 and <15,  
Moderate OSA: AHI ≥15 and <30 and  
Severe OSA: AHI ≥30.  
Zero to <5 is commonly assessed as normal.  
Oxygen desaturation: any event with a 3 % drop in blood oxygen levels, and the index 
(ODI) is the number of desaturation episodes per hours (42).  
The screening and assessment for sleep apnoea is updated in JAMA 2017 and criteria have 
not changed (43). The polygraphy equipment software used in study IV is screening for both 
the AHI and ODI, Embletta (ResMed Sweden AB, Kista Sweden)/ Nox Sleep monitor (Nox 
Medical, Iceland) (44, 45). The program also provides, minimum blood oxygen saturation 
(SpO2) level measured, during each desaturation episode, called the oxygen desaturation 
episode nadir. 
Transcutaneous measurement of partial pressure of oxygen (SpO2) and carbon dioxide 
(TcpCO2 or TcCO2) is an alternative method to explore breathing disorders (Tosca 
Radiometer Medical ApS, Denmark). 
Epworth Sleepiness Scale (ESS)(46): a questionnaire used for screening for obstructive 
sleep disorder; is graded:   
0-5: Lower Normal Daytime Sleepiness,  
6-10: Higher Normal Daytime Sleepiness,  
11-12: Mild Excessive Daytime Sleepiness,  
13-15: Moderate Excessive Daytime Sleepiness and  
16-24: Severe Excessive Daytime Sleepiness. 
Among women of reproductive age the prevalence of OSA is approximated to 5-6% and in 
overweight parturients with BMI 25-30 there is a twofold increase in risk compared to 
women of normal weight during pregnancy (47, 48). In Sweden obesity is increasing, also 
seen in pregnancy but not yet reaches the incidence of USA or UK. In 2013 25% of pregnant 
women in Sweden were overweight and 13% obese with variation for different parts of 
Sweden. In Stockholm 8,7% were obese (49). 
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2.6 RESPIRATION DURING PREGNANCY 
The pregnant woman has several physiological changes regarding ventilation due to 
increased levels of hormones. The upper airway may be narrowed by hyperaemia, airway 
mucosal oedema and vasomotor rhinitis is caused by rise in oestrogen. On the other hand rise 
in progesterone enhances sensitivity to carbon dioxide resulting in stimulated respiratory 
drive with increased minute ventilation and respiratory alkalosis. 
 
2.7 EMERGENT CAESAREAN SECTION 
ECS can be performed during general or regional anaesthesia. Historically introduction of 
regional anaesthesia during CS lowered the anaesthesia maternal mortality. The risk 
difference has decreased from 17:1 for general anaesthesia versus regional anaesthesia during 
1979-1990 to 1.7:1 during 1997-2002 mostly due to better handling of general anaesthesia 
and airway problems (50). A majority of maternal deaths associated with GA is however still 
due to intubation failure (50). Most often GA is chosen when start of operation, incision, is 
wanted within 15 minutes from decision, that is in the most urgent cases and in cases where 
RA not is recommended like in severe cases of haemorrhage or haemodynamic instability. In 
addition to risk-benefit in favour for RA, the effective post-caesarean analgesia provided 
when neuroaxial opioids are used, is to be considered. An urgent CS is a very dramatic event 
with high logistic and psychological demands on the whole team involved. There is a time 
recommendation that an urgent CS is to be performed with delivery within 20 – 30 min. after 
decision, Decision to Delivery Interval (DDI). Swedish Society for Obstetric Anaesthesia and 
Intensive Care (SFOAI) state an anaesthetist should be available within 5 min. where there is 
a delivery department, and option to start to operate within 15 min. from decision but all 
these timeframes are more like tools for auditing obstetric anaesthesia service and with little 
evidence to support medical benefit, though it is clear that some neonates need immediate 
delivery (51, 52). The degree of CS urgency is categorized by Lucas et al. into a four-
graded scale to facilitate communication:  
Category 1) immediate threat to life of woman or foetus;  
Category 2) maternal or foetal compromise that is not immediately life-threatening; 
Category 3) needing early delivery but no maternal or foetal compromise; and  
Category 4) at a time to suite patient and maternity team (53). 
 
2.8 ANNUAL BIRTHS AND ROUTINES  
In Sweden 2014 annual birth-numbers were about 114000 and about 18% were delivered as 
CS; 46% as non elective CS (8.1% of births), and the rest as elective CS (54). In Danderyd 
hospital we had during 2016 10749 births and 2394 CS in the two delivery departments 
Danderyd and BB Stockholm, of which 1119 were emergent (47% of CS and 10.4% of 
births). We administered 4693 labour epidurals during 2016, that is 44% of all births but 
since 1174 had elective CS done, 49% of the patients going for vaginal births had labour 
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epidural. Our labour epidural routines are: as start-dose we inject in total 15 ml of 
bupivacaine 0.1% and sufentanil 0.5 µg/ml, and as maintenance midwifery administered 10 
ml boluses at maternal request about up to hourly. Midwives are encouraged to contact 
anaesthesiologist if there is decreasing effect, or other problems with the epidural to keep 
an optimal analgesia.  
Danderyd Hospital is apart from the delivery units a large emergency hospital with about 
520 beds for general, orthopaedic and gynaecological surgery, internal medicine and 
cardiology. All anaesthesia services, including 8 beds of intensive care is managed by two 
anaesthesia specialists and one anaesthesia registrar in house on call. During on call time, 
there are at least three surgical teams, each consisting of: one anaesthesia nurse, one scrub 
nurse and one or two assistant nurses. One surgical team is reserved for the women’s 
surgical department. Another surgical team from the general surgical department located in 
the same building and within reach of 1-2 min. will assist in case of obstetric emergency 
collisions. When the regular operation program is running, during daytime Monday- Friday, 
there is always one OR spared, ready for urgent CS. The primary OR for ECS is located 
central of the largest delivery department, on the same floor and close to the women’s 
surgical department (within reach in 30–60 seconds).  
 
2.9 LOWEST EFFECTIVE DOSE, BENEFIT VS. RISK 
It is important to adjust the ITM dose to the lowest effective dose maintaining a reassuring 
benefit vs. risk profile. Effects of different low doses of ITM in combination with local 
anaesthesia for spinal anaesthesia for CS to reduce postoperative pain are well studied and 
documented. There are however sparse data around minimal effective dose as adjunct to local 
analgesic in labour and hysterectomy. Use of ITM has become well accepted in CS and lower 
abdominal surgery to improve the postoperative quality. The national praxis of its use as 
adjunct for spinal anaesthesia in CS and low abdominal surgery in Sweden has however not 
been studied. ITM is associated with a small but risk for respiratory depression that can 
compromise safety. In obese mothers there is a greater risk, even though still low risk, for 
respiratory impairment after ITM compared with normal weight. The monitoring of patients 
at risk is still not well defined and there is room for further studies around monitoring 
respiration in at risk patients. Portable polygraphy sleeping apnoea devices monitoring after 
CS in spinal anaesthesia including ITM have not been extensively explored. Spinal (SA) and 
top up epidural (tEDA) are potential alternatives in ECS to reduce the risk associated with 
emergent general anaesthesia. Time to establish surgical anaesthesia is of importance in the 
emergent setting and time limits are proposed. General anaesthesia is preferred in most urgent 
cases, but regional anaesthesia (RA) may be a safe option if situation allows. How routine 
practice utilising different anaesthesia based on clinical situation, GA and RA – SA or tEDA, 
including neuroaxial opoids- with regard to DDI time, keeping set quality limits is not 
extensively documented.  
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3 AIMS OF THE THESIS  
This project aimed to gain knowledge of intrathecal morphine during labour and in caesarean 
section and hysterectomy.  
 
Study I  
To evaluate the impact of supplementing two intrathecal morphine doses: 50 and 100 µg and 
placebo control (saline) to intrathecal labour analgesia with bupivacaine 1.25 mg and 
sufentanil 5 µg on duration, in a double-blind placebo-controlled trial. 
 
Study II  
To evaluate the impact of supplementing three intrathecal morphine doses: 100, 200 and 300 
µg and placebo control (saline) to hyperbaric bupivacaine 12 mg, on postoperative total 
accumulated consumed intravenous morphine, analgesic effect, and occurrence and severity 
of side effects, during the first 24 hours after elective abdominal hysterectomy under general 
anaesthesia.  
 
Study III  
To assess the routine use of intrathecal and epidural morphine in obstetric and gynaecological 
patients, factors that limit/holdback its use and postoperative monitoring after intrathecal 
morphine in Sweden. 
 
Study IV  
To assess postoperative occurrence of apnoea/hypopnea and oxygen desaturation events per 
hour (AHI and ODI) in obese mothers the first night after CS with bupivacaine/ morphine/ 
fentanyl spinal anaesthesia and evaluate the use of portable respiratory polygraphy, for 
respiratory monitoring in this at risk cohort. 
 
Study V  
To assess the impact of anaesthetic technique, general anaesthesia vs. regional spinal / 
epidural top up and work shift on the DDI in emergency CS, with a decided DDI <30 minutes 
at our hospital, Danderyd Hospital (emergency category 1 and most urgent category 2 CS). 
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4 METHODS 
4.1 STUDY DESIGNS 
Table 1. Overview of study designs, study populations and analyses. 
 Study Design Study population Number  Analysis  
Study 
I 
Randomized 
placebo controlled 
double blind trial 
Nulliparous women, ASA I 
– II, requesting epidural 
analgesia during 
spontaneous labour, 
cervical dilatation ≤ 7 cm  
90 à 
78 
analysis 
 
Log-rank analysis to 
compare median time of 
cumulative analgesic 
duration obtained from 
Kaplan–Meier analysis. 
Study 
II 
Randomized 
placebo controlled 
double blind trial 
Women ASA I-II between 
30 and 70 years of age, 
scheduled for abdominal 
hysterectomy with low 
transverse incision 
144 à 
136 
analysis 
Morphine requirement and 
VAS scores were analysed 
with nonparametric tests, 
Kruskal–Wallis analysis of 
variance, and Mann–Whitney 
U-test as appropriate 
Study 
III 
Questionnaire 
survey 
Anaesthesiologists in 
charge of obstetric 
anaesthesia units in 
hospitals in Sweden. 
47 à 
32 
responding 
Descriptive 
Study 
IV 
Prospective 
postoperative 
explorative  
observational 
study 
Parturients with BMI >30 
kg/m2 at the first antenatal 
consultation, who planned 
for elective CS with low 
transverse incision 
performed using standard 
spinal anaesthesia  
23 à 
20 
analysis 
Differences: with Student’s t-
test for continuous variables 
and Chi-squared test for 
categorical data 
Study 
V  
Retrospective 
chart review 
study, using a 
proforma protocol 
Emergency CS needing 
the alarm, expected 
delivery immediately and 
up to a decision-delivery 
interval of 30 minutes 
150 à 
135 
analysis 
Comparing means: 
 2 variables                    
Mann-Whitney U test 
> 2 or more groups           
Kruskal-Wallis H test  
Chi-square-test for 
categorical data. 
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Table 2. Overview of study designs, study populations, neuroaxial route of administered 
morphine, doses of morphine, neuroaxial mixture and primary variables.  
  
Study 
population, 
design 
 
Morphine 
neuroaxial 
route 
 
Groups 
and dose 
of 
morphine 
µg 
 
 
Other 
neuroaxial 
opioid and 
dose 
µg 
 
Neuroaxial 
local  
anaesthesia 
and dose 
mg  
 
Primary 
variable 
Study 
I 
Labour 
analgesia 
RCT 
Single 
spinal 
analgesia 
(CSE) 
0 /     
50/               
100           
µg 
 
Sufentanil  
5 µg 
Bupivacaine 
1.25 mg                 
Duration of 
analgesia 
 
Study 
II 
Abdominal 
hysterectomy 
postoperative 
analgesia 
RCT 
Spinal 
anaesthesia 
0/  
100/  
200/  
300            
µg 
 
0 Bupivacaine 
hyperbaric  
12 mg + 
Standard 
general 
anaesthesia 
Postoperative 
consumed 
nurse 
administered
+ PCA i.v. 
mg morphine  
Study 
III 
Survey to 
Obstetric / 
Gynaeacol.    
anaesthetists 
Morphine 
spinal / 
epidural 
anaesthesia  
   
 
Use of 
neuroaxial 
morphine 
- Labour 
analgesia          
- Caesarean 
section 
- Abdominal 
hysterectomy 
Study 
IV 
Caesarean 
Section        
BMI > 30 
Postoperative 
observational 
 
Spinal 
anaesthesia 
100 µg Fentanyl 10 
µg 
Bupivacaine 
hyperbaric 
11-12 mg                 
Postoperative
occurrence of 
hypo/apnoea/ 
desaturation          
during sleep 
Study 
V  
Emergency 
caesarean 
section 
Retrospective 
chart review  
Spinal / 
Epidural / 
General 
anaesthesia  
SA:  
100 µg   
 
 
EDA:  
2 mg  
SA: 
Fentanyl 10 
µg 
 
EDA:   
Fentanyl 
50-100  µg     
 
SA: 
Bupivacaine 
hyperbaric 
11-12 mg 
EDA: 
Ropivacaine         
112 -150 mg  
 
       
DDI and 
impact of 
chosen 
anaesthetic 
technique                   
(GA /SA / 
EDA) and 
work shift 
 
4.1.1 Study I  
This randomized, doubled-blind placebo-controlled trial was conducted in Danderyd 
Hospital and Karolinska University Hospital.  
Study population: Healthy nulliparous women, in spontaneous labour with a cervical 
dilatation ≤ 7 cm, requesting epidural analgesia in labour, were included.  Only parturient 
with a term singleton foetus in the vertex position were included.  
Randomization: Computer-generated blocked randomization for the two institutions was 
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performed into one of three groups: intrathecal morphine 50 µg (M50), 100 µg (M100), or 
an equal volume of saline (M0) each to be added to bupivacaine 1.25 mg and sufentanil 5 
µg to a total volume of 2.5 mL.  
CSE was performed with a needle-through-needle technique at L3–4 or L4–5. The study 
solution was injected after observing free flow of cerebrospinal fluid. The spinal needle was 
then removed and the epidural catheter was inserted, not to be used during study period, but 
to ensure following pain treatment after the spinal analgesia had decreased and additional 
analgesia was requested.  
Pain was monitored with a visual analogue scale (VAS) where 0 = no pain and 10 = worst 
possible pain. Women were assessed immediately before and at 5 min intervals after 
intrathecal injection for the first 30 min and then every 30 min until a VAS > 4 was 
observed, or additional analgesia was requested.  
Analgesia onset time was defined as the time from intrathecal injection to VAS ≤ 4. 
Successful spinal analgesia was defined as VAS ≤ 4 within 30 min of intrathecal injection. 
The primary outcome: Duration of spinal analgesia was defined as the time from the 
intrathecal injection to VAS > 4 or request for additional analgesia. Secondary outcomes 
were onset time, occurrence of side effects and maternal satisfaction. 
Sensory level to cold, assessed in the mid-clavicular line bilaterally, and motor blockade 
using a modified Bromage scale were recorded. Blood pressure, heart rate, pruritus, nausea, 
sedation and respiratory depression were documented and treated as required.  
Figure 1. Primary outcome for Study I was duration of spinal analgesia. We set an extended 
duration of analgesia of more than 30 min to be of clinical value. 
 
 
4.1.2 Study II 
This randomized, doubled-blind placebo-controlled, trial was conducted in Danderyd 
Hospital (n = 100) and Karolinska University Hospital (n = 44) between 2005 and 2008.  
Study population: Women, ASA I-II between 30 and 70 years of age, scheduled for 
Spinal injection Pain VAS > 4 
> 30 min 
5 min 30 min 60 min 90 min 
VAS is checked 
Primary outcome 
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abdominal hysterectomy with low transverse incision, were included. Patients on regular 
pain medication, ASA III-IV, or contraindications to spinal anaesthesia were excluded. 
Randomization: Computer-generated blocked randomization for the two hospitals was 
performed into one of four groups: intrathecal morphine, 100, 200, and 300 µg or an equal 
volume, 1 ml of saline as placebo as supplement to hyperbaric bupivacaine 0.5%, 2.4 ml 
(12 mg) to a total volume of 3.4 ml. All patients were included and completed the study 
before the randomization code was revealed.  
Preoperatively all patients were given paracetamol 1.5 g orally, and paracetamol was 
continued with 1 gram every 6 hours according to the routines at our departments. 
Nonsteroidal anti-inflammatory drugs (NSAID) were not used. If needed, oxazepam was 
given as anxiolytic. Infusion of Ringer’s acetate solution was initiated prior to spinal 
anaesthesia.   
Spinal anaesthesia was performed with bupivacaine and study drug as described, using a 25 
G pencil point needle in the L3-L4 or L4-L5 interspace after confirming free flow of 
cerebrospinal fluid.  
Standard general anaesthesia was induced after sensory level to cold was checked. Fentanyl 
0.1 mg, propofol 2–3 mg/kg, and atracurium 0.5– 0.6 mg/kg i.v. was administered and 
anaesthesia was continued, after tracheal intubation, with a mixture of oxygen and nitrous 
oxide – 30/70% with addition of sevoflurane to minimal alveolar concentration (MAC) 1–
1.5. All patients received droperidol 1 mg and betametason 4 mg i.v. to reduce the 
incidence of post-operative nausea and vomiting. Morphine 0.1 mg/kg was administered 
i.v. 30 min. before ending operation, for good post-operative pain treatment. Time for 
extubation was considered time zero.  
Pain was monitored with a visual analogue scale (VAS) where 0 = no pain and 10 = worst 
possible pain in the post-anaesthesia care unit (PACU).  Patients stayed in the recovery area 
during the first post-operative night.  
Rescue pain treatment, morphine 0.05 mg/kg, was administered i.v. if pain VAS > 4, by the 
nurse in PACU, every 5 min. until VAS < 4.  
Morphine PCA was connected 1 h after end of anaesthesia when the patient was awake and 
able to use this. We programmed the PCA to administer boluses of 2 mg of morphine, with 
a lockout time of 6 min and maximum of 40 mg within 4 hours. 
The primary outcome: the postoperative total accumulated amount of morphine 
consumed. The secondary outcomes were morphine consumption on the first 0–6 h, 6–12 h, 
and 12–24 h, postoperative pain at rest and at movement, nausea, pruritus, sedation, oxygen 
saturation, respiratory rate, heart rate and blood pressure.  
Adverse events were treated according to the routines at our departments. Pruritus was 
treated with clemastin 2 mg i.v. Nausea and vomiting was managed with ondansetron 4 mg 
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i.v. which could be repeated. When pharmacological intervention for pruritus, nausea, and 
vomiting was administered to patients, they were considered to have experienced that side 
effect. Naloxone was to be provided at the discretion of the anaesthesiologist in case of 
respiratory depression, severe pruritus, or sedation.  
Figure 2. Primary outcome Study II is total postoperative accumulated morphine 
consumption. 
 
4.1.3 Study III  
Population: Anaesthesiologists in charge of obstetric anaesthesia in the 47 delivery units in 
Swedish hospitals were invited to answer a questionnaire.  
Collection of data: In December 2014 the questionnaire was sent by email together with a 
letter to the anaesthesiologists. In April 2015 this was repeated, with an additional postal 
mail to those clinics that had not replied. The clinics that did not return answer were phoned 
to ensure right anaesthesiologists were addressed. The survey was e-mailed in two versions: 
a Word document, to fill in and save by the computer, and return by email to a study email 
address, and a PDF-file to print and fill in by hand if this was chosen, and send by post to 
our hospital address.  
The questionnaire consisted of 26 questions to reflect the routine use of morphine, 
fentanyl and sufentanil as supplement to local anaesthetic, in spinals and epidurals for CS, 
hysterectomy and other gynaecological operations, in the different units. Questions about 
the routine use of ITM for labour analgesia were also included. (Study III, questionnaire in 
English) The questionnaire contained both multiple choice and full written answers.  
We asked for approximated numbers of CS and hysterectomies performed in spinal and 
Extubation 
1 h 
VAS checked  
If VAS > 4 
Nurse 
administer  
0.05 mg/kg 
every 5 min 
until VAS < 4 
NCA = 
Nurse 
Controlled 
Analgesia 
2 h 4 h 6 h 12 h 24 h 
PCA =  
Patient Controlled Analgesia 
connected at 1 h 
i.v. dose 2 mg, 
lockout time 6 min 
 
Primary outcome:  
Total postoperative accumulated morphine, NCA + PCA 
Secondary outcome:  
•  Morphine consumption first 0-6h, 6-12 h and 12-24 h 
•  Postoperative pain at rest and movement 
0 
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epidural anaesthesia, respectively, and numbers of patients administered with opioids, 
especially neuraxial morphine, including doses for the operations performed.  
We asked for reasons behind excluding supplementation of intrathecal/epidural morphine 
when they have chosen not to use it.  
Questions to reflect organisation of monitoring after intrathecal / epidural morphine 
administration, and occurrence of known serious adverse events in their units were also 
included.  
 
4.1.4 Study IV  
This prospective observational study was conducted in Danderyd hospital from December 
2015 to October 2017.  
Study population: Obese parturients, planned for elective CS with low transverse incision 
in standard spinal anaesthesia, were included after information and consent at the pre-
anaesthetic consultation. Obesity was defined as BMI >30 kg/m2 registered at the first 
antenatal consultation. Patients with diagnosed obstructive sleep apnoea (OSA) receiving 
treatment, like continuous positive airway pressure (CPAP) or mouth guard, any known 
contraindication to ITM or language difficulties were excluded. 
All patients filled in a standardised Epworth Sleepiness Scale (ESS) questionnaire (46). 
Preoperatively the patients received 1.5 g paracetamol orally, and paracetamol was 
continued postoperatively 1 g every six hours or 1.330g every eighth hours. Ibuprofen (400 
mg) was administered every eighth hours.  
Spinal anaesthesia was performed using a 25-gauge pencil-point needle with the patient in 
left lateral or sitting position, at the patients and/or anaesthetists’ preference, according to 
standard routines for CS in our department. A mixture of hyperbaric bupivacaine (11–12 
mg), fentanyl (10 µg) and morphine (100 µg), was injected intrathecally to all patients. 
Hypotension was prevented by our ordinary routines; left lateral position to reveal aorto-
caval compression, co load of Ringer lactate and phenylephrine/ephedrine injections. 
Routine monitoring after spinal CS anaesthesia in the postoperative and obstetric ward 
includes the following: heart rate and blood pressure; control of uterine contraction and 
bleeding; pain by NRS/VAS; urine output; control of sedation, and if sedated counting RR 
every hour; mobilization; and breast feeding. Patients are encouraged to mobilize, stand by 
the bed, at about 5–6 hours postoperatively. Urine catheter is usually removed after the first 
postoperative night. During the 3–5 first hours postpartum, the patients were continuously 
observed awake in the postoperative department. 
Extended postoperative study monitoring added to routine monitoring: a portable OSA 
polygraphy monitor with a finger probe to measure oxygen saturation, nasal catheter to 
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measure expiration flow and thoracic and abdominal strings to register breathing 
movements, (Embletta - ResMed Sweden AB, Kista, Sweden/Nox Sleep monitor - Nox 
Medical, Iceland); and a combined ear-probe for transcutaneous carbon dioxide 
(TcCO2)/oxygen saturation (SpO2) monitor (Tosca Radiometer Medical ApS, Denmark). 
After the first 3-5 postoperative hours of routine monitoring, polygraphy and Tosca 
registration was applied during rest/sleep the first postoperative afternoon and night.  
Adverse events such as pain NRS > 3, nausea and vomiting or pruritus were managed 
according to the department’s routines.  
Figure 3.  Monitoring after CS in Study IV 
 
4.1.5 Study V  
This is a retrospective chart review study using a proforma protocol. No intervention was 
initiated by or associated with the present study. 
Study population: alarm logs and patient records for all ECS (category 1 CS and some 
urgent category 2 CS) at Danderyd Hospital from 1st of January to October 31st 2016 were 
collected and analysed. 
Data collection: We retrieved time events; start time of anaesthesia, start and end of 
operation and type of performed anaesthesia from our electronic surgical registration 
system (Orbit 5.7) after matching time of the event from the ECS alarm logs. Time of 
delivery, the foetal status and neonatal need of treatment was collected from the patient 
journal. 
End of CS 
First 3-5 h 
postoperative  
continously 
observation awake in 
postoperative / 
obstetric department  
3-5 h 12 h 15-21 h 
8:00 next  
morning 
Night time respiratory monitoring device - 
Portable Polygraphy registration + 
Transcutaneous combined CO2 + O2 
monitor 
Routine monitoring  
•  Sedation,  respiratory rate if sedated 
•  Postoperative pain at rest and movement 
•  Heart rate, blood pressure 
•  Uterine contraction, bleeding, urine output 
•  Mobilization, breast feeding  
•  Time of urinary catheter removal, urinating, discharge 
0 
AHI = Apnoea Hypopnea index 
ODI = Oxygen Desaturation Index 
TcCO2 =Transcutaneous carbon dioxide 
SpO2 = Oxygen saturation 
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Figure 4.   Time events from Decision of ECS to Delivery, at time for decision expected 
delivery within 30 minutes. 
 
When the obstetrician presses the alarm for ECS, at least one experienced anaesthesiologist 
is called together with anaesthesia and scrub-nurses and a neonatologist. We have been 
working with the alarm and communication process to facilitate use of regional anaesthesia.   
Decision on ECS needing immediate delivery, in the most severe cases: The attending 
obstetrician presses the alarm gathering the surgical team together with anaesthesia 
specialist, anaesthesia registrar and neonatologist. The obstetrician follows the patient to 
hasten the process. 
Decision on ECS needing delivery within 30 minutes, estimated by the obstetrician: The 
obstetrician first informs the anaesthesia specialist by phone with report by SBAR, 
including whether regional anaesthesia is an option and if there is a labour epidural to top-
up, and then presses the alarm to gather the team.  
Anaesthetic technique: The attending anaesthesiologist decides on anaesthetic technique 
according to routines at our department. When an immediate delivery is urged GA is 
recommended in most cases. GA is based on pre-oxygenation followed by a rapid sequence 
induction with propofol and suxamethonium, intubation and sevoflurane until delivery. 
When need for delivery is expressed within 30 min. spinal anaesthesia (SA) or top-up 
epidural (tEDA) is recommended. A rapid SA is chosen if there is time and a well working 
labour epidural anaesthesia is not established. SA is performed with hyperbaric bupivacaine 
(approximately 2.4 ml; 5 mg/ml), morphine (100 µg) and fentanyl (10 µg). Top-up of a well 
working labour epidural, is chosen when mother and child’s status allow, with ropivacaine 
(approximately 15 – 20 ml; 7.5 mg/ml) and fentanyl (100 µg). The routine is to start the top 
up dose outside, but close to, the OR, within reach in 30-120 seconds, when it seems 
appropriate. This requires the anaesthesiologist to follow with the patient, to enable close, 
continued supervision. 
Decision of ECS  
= Alarm Call  
Start of 
Anaesthesia 
Decision to Delivery Interval 
0 
Ready for 
surgery - 
Incision 
Delivery 
Apgar  
at 5 min. 
Call to Start of 
Anaesthesia 
Start of Anaesthesia 
to Ready for surgery Surgery to Delivery 
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4.2 STATISTICS 
4.2.1 Study I  
Power analysis: Based on former studies of the duration of single spinal labour analgesia 
with combinations of bupivacaine and fentanyl or sufentanil a power analysis was conducted 
(34, 55). We set an extended duration of analgesia of more than 30 min. to be of clinical 
value and with a power of 0.80 and α < 0.05, 27 women in each group were required. The 
sample size was increased to 30 in each group, as we expected 10% dropout rate.  
Analysis of results: Normally distributed continuous variables were compared using 
Students’t-test or analysis of variance. Categorical data were analysed using chi-square test 
and Fisher’s exact test. P < 0.05 was considered significant. To assess the cumulative 
proportion of continued spinal analgesia, Kaplan–Meier survival analysis was used. Log-rank 
analysis was then used to compare median time of cumulative analgesic duration obtained 
from Kaplan–Meier analysis. Spearmans’ rang correlation was used to assess correlations.  
4.2.2 Study II  
Power analysis: We estimated morphine consumption in the control group to 40 mg for each 
patient and a standard deviation of 8 mg, based on former studies with spinal bupivacaine 
anaesthesia (12–15 mg) combined with general anaesthesia (56, 57). A 30% reduction of 
morphine consumption was assumed to be of clinical value. To detect a 30% reduction with a 
power of 0.80 and α < 0.05, 33 women in each group were required. As we expected a 10% 
dropout rate, the sample size was increased to 36 in each group. 
Analysis of results: Normally distributed continuous variables were compared by using 
Student’s t-test or two-way analysis of variance. Morphine requirement and VAS scores were 
analysed with nonparametric tests, Kruskal–Wallis analysis of variance, and Mann–Whitney 
U-test as appropriate.  Categorical data were analysed using Chi-square test and Fisher’s 
exact test. P < 0.05 was considered significant. 
4.2.3 Study III  
Data is presented as number and percentage, and range as applicable. In order to put our 
results into perspective, with regards to the impact of routine use of opioids, we used annual 
total number of performed CS in the obstetric unit to approximate the size of the different 
units. We got the annual numbers from The Swedish Medical Birth Register from National 
Board of Health and Welfare (Sweden). We used no formal statistical tests in Study III. 
4.2.4 Study IV  
Data is presented as the mean and standard deviation; categorical data are presented as 
frequencies. The study is explorative and observational, thus no power analysis has been 
conducted.  
Analysis of results: Differences have been studied with Student’s t-test for continuous 
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variables and Chi-squared test for categorical data. Spearmans’ rang correlation was used to 
assess correlations. 
4.2.5 Study V  
Descriptive statistics regarding the ECS and the variables was made using mean, standard 
deviation (SD) and range, as well as median and interquartile range (IQR), as appropriate.  
Analysis of results: Mann-Whitney U test was used for comparing means between two 
variables and Kruskal-Wallis H test was used when comparing two or more groups. Chi-
square-test was used for test of differences between categorical data. A p-value <0.05 was 
considered significant. 
4.3 ETHICAL CONSIDERATIONS 
Ethical permits have been obtained for study I, II, IV and V from Regional Ethics 
Committee in Stockholm, Sweden. Patients were accurately informed both verbal and in 
writing and provided written consent. Study III is a survey concerning only clinical practice 
and routines. No patient data was included. Ethical committee approval was not applied for, 
in accordance with Swedish ethical board guidelines and with the principles outlined in the 
Declaration of Helsinki.  
Since Studies I and II include drug interventions, permits have been obtained from Medical 
Product Agency, Sweden as well, in accordance with GCP. Studies I and II are placebo 
(saline) RCT’s and all patients got good pain-relief, the placebo groups had proven efficient 
component intrathecally as well, followed by epidural and PCA administration respectively. 
The practiced method, in Study I, Combined Spinal Epidural (CSE), is routinely used in 
delivery units, and does not show extra risks. CSE was used to ensure good pain relief during 
labour after spinal analgesia had diminished. Study IV implicate technical intervention with 
more extended monitoring than with routine care, that might affect ability of rest, sleep and 
contact with the new-born baby for mothers, first night after caesarean section. However the 
polygraphy equipment is small, made for home use, not invasive, and could be moved when 
mothers were awake so it would not interfere with breastfeeding and have minimal effect on 
the mother-and-child contact. Obese mothers have been shown at extra risk for respiratory 
impact postoperatively, and there is a lack of knowledge, thus we found it reasonable to 
accomplish the study. We preferred to start with an explorative observation study on this 
cohort at risk mothers, to find if further studies including control group would be warranted. 
We did not want to include mothers as controls before we had findings supporting further 
studies.  The monitoring equipment and analysis of results were used and made in close 
cooperation with the well-established team in our department that do this on daily basis. 
Study V was retrospective with a proforma protocol or “prospective with no study-
intervention” chart review with only neonatal data picked from patient journal and no 
individual identity-data collected and we found no ethical considerations. 
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5 RESULTS 
5.1.1 Study I 
We enrolled 48 labouring women from Danderyd Hospital and 42 from Karolinska 
University Hospital; 82 women obtained adequate pain relief from the intrathecal injection 
and 78 of these continued labour until return of pain, VAS > 4 and were included in final 
analysis of duration, with 26 in each group M0/M50/M100.   
Inadequate pain relief from the spinal injection within 30 minutes, was reason to exclude 
eight women and four delivered before return of VAS > 4; two from the M50 group were 
delivered vaginally at 92 and 162 min, respectively. The other two were from the M0 
group: one parturient had a normal vaginal delivery after 157 min and one had non-
reassuring foetal heart rate pattern and thus urgent delivery by vacuum extraction. In the 
Kaplan–Meier survival curve for cumulative duration of VAS < 4 these subjects are shown 
as censored observations and otherwise excluded from statistical analysis of duration (Fig. 
5).  
Table 3 present maternal data, initial cervical dilatation and VAS before intrathecal 
injection. There were no significant differences between groups in duration of analgesia, 
onset time, subsequent epidural bupivacaine requirement, pruritus or maternal satisfaction 
(Table 4, Figs. 5 and 6). Onset time was not affected by the degree of cervical dilatation at 
entry to the study, Spearman’s correlation coefficient, (r  = 0.187; P  = 0.093) nor was the 
duration of analgesia (r = - 0.098; P = 0.39) (Figs. 7 and 8). Time to onset or effective 
analgesia was not affected by the degree of cervical dilatation when the spinal injection was 
administered, no difference was seen between patients with cervical dilatation 3–5 and 6–7 
cm. 
Oxytocin during labour was administered to most labouring women, with no difference 
between groups, the majority starting after spinal injection. There were no differences in 
obstetric and neonatal outcome (Table 5). No woman required treatment for hypotension, 
nausea, sedation or respiratory depression. No woman was reported having PDPH, four 
days after delivery. No significant differences between groups were found regarding 
satisfaction with analgesia; in fact all women answered either very satisfied or satisfied.  
Table 3.  Personal and baseline data 
 M0  
n=28 
M50  
n=28 
M100 
n=26 
Age [years]  30 [22–37] 31 [22–38] 29 [20–40] 
Weight (kg)  80 (11) 83 (11) 78 (9) 
Height (cm)  166 (6) 167 (7) 168 (6) 
Cervical dilatation at entry (cm) 5.0 [3–7] 5.0 [3–7] 4.5 [3–6] 
VAS pre spinal  9.2 [8–10] 8.7 [6.5–10] 8.6 [6.5–10] 
Data are median [range] or mean (SD) 
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Figure 5. Kaplan–Meier 
showing proportion of 
women with VAS ≤4 in 
M0, M50, M100 groups 
after intrathecal injection. 
Crosses represent subjects 
who delivered before 
return to VAS > 4. No 
differences between the 
groups. 
 
 
 
Figure 6. Box-plot of 
VAS during onset of 
analgesia in M0, M50 and 
M100 groups. Boxes 
show lower quartile, 
median and upper 
quartile. Dots represent 
outliers.  
No differences between 
the groups. 
 
 
 
Table 4. Spinal analgesia block characteristics 
 M0  M50  M100 
 
Onset (time to VAS≤ 4) minutes, Mean ± SD (n) 
[range]  
7.7 ± 4.4 (28)  
[5–25] 
9.6 ± 5.1 (28)   
[5–25] 
8.8 ± 5.5 (26) 
[5–25] 
Duration minutes Mean ± SD (n)  
[range]  
113 ± 50 (26) 
[60–240]  
116 ± 32 (26) 
[60–203] 
100 ± 38 (26) 
[50–210] 
Sensory block height to cold Median [range] T7 [T4–T12] T8 [T2–T10] T7 [T4–T12] 
Motor block Bromage ≥1    n (%) 1 (4)  2 (8)  0 
Hypotension >20%             n (%)  3 (11)  1 (4)  2 (8) 
Pruritus                               n  (%)  15 (58)  17 (61)  15 (58) 
Maternal satisfaction              % 
    very satisfied  
    satisfied  
 
79 
21 
 
92 
8  
 
88 
12 
Epidural requirement (mL/h) mean ± SD 4.9 ± 2.9 4.2 ± 3.1 6.9 ± 6.6 
Data are mean ± SD, median [range] or number / %. 
Duration 
Mean ±SD 
 
M0  
113 ± 50 
 
M50 
116 ± 32 
 
M100 
100 ± 38 
Onset 
Mean ±SD 
 
M0  
7.7 ± 4.4 
 
M50 
9.6 ± 5.1 
 
M100 
8.8 ± 5.5 
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Figure 7. The figure shows the variation in 
onset time without correlation with 
cervical dilatation at entry to the study. 
 (Spearman’s correlation coefficient,           
(r = 0.187; P = 0.093)  
Each dot may represent more than 1 
patient. 
 
 
 
 
Figure 8. Cervical dilatation at entry to the 
study did not affect duration of analgesia                                 
(Spearman’s correlation coefficient,                  
(r = - 0.098; P = 0.39) 
 
 
 
 
 
Table 5. Obstetric and neonatal outcome 
 M0  
n =28 
M50 
n =28  
M100 
n =26 
Duration of labour, min. 456 (293) 424 (185) 376 (212) 
Oxytocin infusion  26 [93] 26 [93] 26 [100] 
Mode of delivery  
    Normal vaginal delivery 
    Instrumental delivery 
    Caesarean section 
 
14 [50] 
10 [36] 
  4 [14] 
 
19 [68] 
  8 [29] 
  1 [4] 
 
17 [65] 
  6 [23] 
  3 [12] 
Apgar score < 7 at 5 min  0    1 [4]    1 [4] 
Umbilical artery  
    pH 
    pCO2  
    base deficit  
 
7.25 (0.14) 
7.32 (1.65) 
6.49 (2.64) 
 
7.23 (0.16) 
7.38 (1.66) 
7.24 (4.02) 
 
7.20 (0.11) 
7.93 (1.63) 
6.80 (3.88) 
Data are mean (SD), or number / [%]. 
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5.1.2 Study II 
Of the 144 women having abdominal hysterectomies in spinal anaesthesia including 
morphine during general anaesthesia enrolled, 136 were included in statistical analysis. 
Eight women were excluded from statistical analysis. Midline instead of Pfannenstiel 
incision was used in five patients. By mistake NSAID was administered to two patients and 
a wrong dose of ITM to one patient. The Consort flow chart for the study is shown in Fig. 
9.  
Demographics and perioperative data for the four groups were comparable (Table 6).  
Postoperative morphine consumption: All three groups receiving ITM showed reduced 
accumulated 24 h post-operative morphine consumption (Table 7, Fig. 10). Analysing 
values as medians, morphine consumption vs. placebo was significantly reduced by 
Morphine 100 µg at 0–6 h, 6–12 h, and for the entire 0–24 h time interval post-operation 
(Table 7). Morphine consumption as compared with morphine 100 µg was further 
significantly reduced by Morphine 200 µg at 0–6 h and for the entire 0–24 h time interval 
post-operation (Table 7). We saw no further reduction of morphine consumption with 
morphine 300 µg and no difference regarding the quality of analgesia vs. morphine 200 µg. 
Analysing values as mean we found Morphine 100 µg reduced morphine consumption vs. 
placebo at 0-6 h and for the entire 0-24 time interval while Morphine 200 µg reduced 
morphine consumption vs. placebo at all-time intervals 0-6 h, 6-12 h and 12-24 h (Table 7, 
Fig 10).  
Postoperative pain is shown in Table 8. A significant reduction in pain was observed when 
comparing the first 12 h pain VAS score between all three groups receiving ITM and the 
placebo control group, (P < 0.05). No difference was seen regarding pain at rest, VAS > 4 
at any time point; 35% in the placebo group of patients and 18%, 22%, and 19% for the 
100, 200, and 300 µg groups, respectively (Table 9). During movement the experience of 
pain, VAS > 4 was more common but still not significantly different between the groups; 
47%, 24%, 32%, and 30% for placebo and morphine escalating dose groups, respectively 
(Table 9).  
Adverse event observations: In 75% of patients minor peri-operative hemodynamic 
variations were treated with ephedrine, without differences between groups. No major 
adverse events or complications were seen during surgery or the 24 postoperative hours 
studied. Table 9 shows the incidence of side adverse events, with only small differences 
seen between the groups. Pruritus occurred solely in morphine groups. Nausea and 
vomiting were seen equally common in all groups (Table 9). No patient developed PDPH. 
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Women, ASA I – II, schedueled 
for abdominal hysterectomi  with 
low transverse incison  
N = 144 
Enrollement 
Random assignment 
Allocated to 
Intervention 
group 
Morphine100 µg  
N = 35 
Correct inclusion 
criteria and 
Received 
allocated 
intervention 
N = 34 
 
Allocated to 
Intervention 
group  
Morphine 200µg  
N = 35 
Correct inclusion 
criteria and 
Received 
allocated 
intervention 
N = 31 
 
Allocated to 
Intervention 
group  
Morphine 300µg  
N = 38 
Correct inclusion 
criteria and 
Received 
allocated 
intervention 
N = 37 
 
Allocated to 
Control  
group  
Placebo 
N = 36 
Correct inclusion 
criteria and 
Received 
allocated 
intervention 
N = 34 
 Did not follow 
protocol 
By mistake 
received NSAID  
N = 1  
Midline incision  
N = 2 
Midline incision  
N = 2 
 
Midline incision  
N = 1 
 
Did not follow 
protocol  
By mistake 
received NSAID  
N = 1 
Did not receive 
allocated 
intervention, got 
wrong morphine 
dose by mistake 
N = 1 
 
Intervention 
group  
morphine 100µg 
N = 34 
Intervention 
group  
morphine 200µg 
N = 31 
 
Intervention 
group  
morphine 300µg 
N = 37 
 
Control  
group  
placebo 
N = 34 
 
Analysis 
Figure 9.    Consort 
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Table 6. Demographics and peri-operative data 
All values are expressed as mean, SD [range], M=morphine 
 
 
Table 7. Morphine consumption (mg) 
Regarding mean:     ◊Significant difference versus placebo, P=0.05   
                               * Significant difference versus M100, P=0.05 
Regarding median: ◊Significant difference M100 versus placebo, P=0.05, ◊◊ P=0.01 
    * Significant difference M200 versus M100, P=0.05, ** P=0.01 
       No significant difference M300 versus M200 
 
 
Figure 10.  Morphine consumption (mg) as mean   
◊Significant difference versus placebo, P=0.05  
* Significant difference versus M100, P=0.05 
 
 
 
 Placebo 
N = 34                  
M100µg 
N = 34 
M200µg  
N = 31 
M300µg 
N = 37 
Age(yr) 51 ± 8 [38-69] 51 ± 8  [38-66] 49 ± 8  [39-62] 51 ± 8  [39-70] 
Weight (kg) 71 ±  12          70 ±  9         71  ± 13          65  ± 8          
Length (cm) 166  ±  6         166 ± 7          166 ± 6          165 ± 6 
Duration of surgery (min) 
                           Range 
95 ± 27  
[42-163]         
102  ± 29  
[60-170]      
101  ± 34  
[50-175]       
95  ± 32 
[40-180)]      
Blood loss during surgery (ml) 307 ± 246  314 ± 221 316 ± 267   272 ± 320 
                           Range [0-1050]      [0-800]    [0-1300]   [0-1350] 
 
 
 Placebo 
N = 34                      
M100µg  
N = 34                     
M200µg   
N = 31                     
M300µg  
N = 37 
Hour 0-6 Mean ± SD 23 ± 12 10 ◊± 9 6 ◊ ±  11 6 ◊ ± 9 
 Median[Range]                                   21 [6-61]       8 ◊◊ [0-35]       2 ** [0-52]       2  [0-40]       
Hour 6-12 Mean ± SD                              10 ± 8 7 ± 9 4 ◊ ± 6 4 ◊± 7 
 Median[Range]                                   8 [0-40] 4 ◊ [0-40]       2 [0-24]       2 [0-34]       
Hour 12-24 Mean ± SD                              15 ± 13 14 ± 11 9 ◊ ± 8 12 ± 12 
 Median[Range]                                   12 [2-64]       12 [0-42]       10 [0-30]       10 [0-49]       
Hour 0-24 Mean ± SD                              48 ± 27       31◊ ± 25       19 ◊* ± 19 23◊± 24 
 Median[Range]                                   42 [19-130] 22 ◊◊ [0-81]       14 * [0-88]       16  [0-116]       
◊ 
◊ ◊* 
mg 
◊ ◊ 
◊ 
◊ 
◊ ◊ 
Placebo                     M100 µg                 M200 µg                 M300 µg 
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Table 8. Adverse events analyses; VAS (pain)  
Values are expressed as median with [range] during postoperative recovery 1 - 24 hours. 
 
 
 
 
 
 
 
Table 9. Adverse events analyses 
Values are expressed as number of patients that experience adverse events,                                                 
 occurring number of times: 0 /1/2/3 or more, during postoperative recovery 1-24 hour. 
No significant difference was seen between any morphine group or groups versus placebo. 
 
 
 
 
 
 
 
 
VAS(pain)  
Postoperative hour 
Placebo 
n =34  or in ( ) 
M100 µg 
n = 34 or in ( ) 
M200 µg  
n = 31 or in ( ) 
M300 µg                
n =37  or in ( ) 
Rest    1 h                           4 [0-9]       3 [0-8]       2 [0-6]       0 [0-7]        
Rest    2 h                           3 [0-8]       2 [0-7] (33)           1 [0-5]  0 [0-5]   
Rest    4 h                           3 [0-8]       1 [0-6]       0 [0-5] (30)               0 [0-6]   
Rest    6 h                           2 [0-4]       1 [0-7]       0 [0-5] 0 [0-4]  
Rest    12 h                           1 [0-6]       1 [0-6]       0 [0-6]       0 [0-7]        
Rest    24 h                           1,5 [0-7]       2 [0-6]       1 [0-6]       1 [0-6]        
Movement   1 h                           4 [0-9] (33)      3 [0-8] (32)      3 [0-6] (28)      1 [0-7] (35)       
Movement   2 h                           3 [0-7] (33)          3 [0-7] (33)          2 [0-5] (30)          1 [0-7]   
Movement   4 h                           3 [0-9]       2 [0-7]       1 [0-5] (30)               1 [0-7]   
Movement   6 h                           3 [0-6]       1 [0-7]       1 [0-5] (30)               1 [0-8]   
Movement  12 h                           1 [0-6]    1 [0-7]       1 [0-6] (30)  1 [0-8]   
Movement  24 h                           2 [0-7]       2 [0-6]       2 [0-6] (30)       1 [0-7]   
 Placebo 
N =34 
M 100 µg 
N = 34 
M200 µg  
N = 31 
M300 µg 
N=37 
 
VAS(pain) rest > 4 22 /5/6/1  28 /4/1/1          24 /5/1/1     30 /5/1/1  
VAS(pain)movement > 4 18 /8/6/2 26 /4/1/3 21 /7/2/1 26 /9/1/1  
Itching rescue medication 34 /0/0 30 /1/3 30 /1/0 32 /4/1  
PONV rescue medication 20 /7/6/1 18 /7/8/1 16 /6/3/6 19 /12/2/4  
HR < 45/min                            33 /1        34 /0       31 /0       36 /1  
Syst. BP < 90 33 /0/1                33 /0/1              28 /3/0            32 /4/1  
Sedation grade1/ 0-3 10 /7/5/12 14 /4/4/13 11 /2/1/17 14 /8/0/15  
Sedation grade 2-3/ 0-3 30 /3/0/1 30 /1/2/1 27 /3/1/0 29 /3/1/4  
Respiratory rate < 8/min 30 /4/0/0             28 /5/0/1            23 /7/ 0/1         34 /1/1/1  
Respiratory rate >20/min 33 /1            32 /2 29 /2 35 /2  
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5.1.3 Study III 
Responding clinics: In total, 68% of obstetric anaesthesia units, (32/ 47) responded to the 
questionnaires, and the sizes of these units correspond to 83% of annual CS in Sweden. 
Responding frequency was correlated to the size of the unit. We got answers from 90% 
(19/21) of the units with over 2000 births/year versus only from 50% (13/26) of the units 
with less than 2000 births/ year. There was 100% response from the 15 units performing 
more than 400 CS/year. 
Caesarean sections (CS)  
Table 10 shows the practice of intrathecal opioids in CS.  At least one opioid was used as 
adjunct to local anaesthesia in all responding units.  
Intrathecal morphine:  In 20 out of 32 units ITM was used routinely in CS spinal 
anaesthesia. Additional three units commented that they intended to change routines within 
the next year and start including ITM. The most common ITM dose was 100 µg, used in 
17/20 units and three units used 125 µg. Combination of morphine with either fentanyl or 
sufentanil and bupivacaine was most common, practiced by all units, except for two. One of 
these units answered that they will start to add fentanyl.  
Intrathecal fentanyl was added in CS anaesthesia in 21/32 units; 5 units used exclusively 
fentanyl, without morphine. The most common dose used was 10–12.5 µg (18 units) and 
15–20 µg doses were used in 3 units. 
Intrathecal sufentanil supplement was less commonly used in spinal CS anaesthesia; 9/32 
units, where sufentanil was added as the sole opioid by seven units. Sufentanil doses were 
either 2.5 µg (4 units) or 5 µg (4 (units) and in one unit a 5–10 µg dose was used.  
 
In total, the combination morphine/fentanyl was most common, used in 16 units, 
combination morphine/sufentanil less common, used in 2 units, and solely morphine used 
in 2 units, solely fentanyl used in 5 units and 7 units used solely sufentanil as supplement to 
bupivacaine in CS spinal anaesthesia.  
One unit that responded routine use of ITM for CS did not include any dose of intrathecal 
morphine, but only sufentanil and is consequently not included in Table 10 among 
morphine use and the unit is considered as none user of ITM. 
Epidural morphine supplement to CS epidural anaesthesia was less common than ITM in 
spinal anaesthesia: 12/32 units. The most common epidural dose of morphine, 2 mg was 
used in 10 units, one unit used 4 mg and one unit used a 1 mg dose of morphine. 
Epidural fentanyl was added (50–100 µg) in the epidural for CS anaesthesia in 10 units. 
Epidural sufentanil was used in 15 units as the opioid with rapid onset of action in the CS 
epidural anaesthesia. Doses up to 10 µg were used in 11 units, doses up to 25 µg were 
administered in 3 units and one unit added a 25–50 µg dose sole sufentanil to local 
anaesthesia.  
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Single spinal labour analgesia.  
None of the units reported use of morphine in spinal labour analgesia.  
Hysterectomy 
 Intrathecal morphine in spinal anaesthesia was administered in hysterectomy in 20 of the 
32 answering units. The dosage was spread, 9 clinics used 200 µg, 5 used 120–140 µg, 
another 5 used 100 µg and one unit administered 80 µg dose of ITM.  
In other gynaecological operations, like other gynaecological abdominal surgery, malign 
robot surgery and perineoraphies, 7 of 32 clinics used ITM. Epidural morphine was used in 
one unit, in malign gynaecological surgery. 
Postoperative monitoring.  
The first postoperative 2–6 hours after CS patients were monitored in either the 
postoperative ward or the obstetrical ward (routinely in eight hospitals and occasionally in 
some hospitals) and the following hours up to 12 hours patients were usually monitored in 
the regular ward. Risk of respiratory depression and difficulties to monitor were noted as 
the main reasons for withholding use of spinal/epidural morphine by seven of the 12 units 
that did not use it.  
Figure 11. The use of intrathecal (left) and epidural (right) opioids as supplement to local 
anaesthetics in CS in Sweden. Impact of routines is expressed as approximated size of 
obstetric anaesthesia units, with regard to total performed CS at the units respectively.  
M=Morphine, F=Fentanyl, S= Sufentanil 
Spinal opioids         Epidural opioids 
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Table 10. The use of opioid supplementation to bupivacaine in CS in different obstetric 
anaesthesia units. To approximate the size of unit and impact of routine, share of total 
performed number of CS in responding units and share of CS in Sweden respectively. 
 
 
Caesarean section  Units  
Share of total performed CS … 
…in the 
responding units 
…in Sweden 
Responding rate  32/47  83% 
In
tra
th
ec
al
 
M
or
ph
in
e 
IT Morphine  20 73% 61% 
IT Morphine dose       100  /125 µg 17/3   
IT Morphine  + fentanyl 16 65% 55% 
IT Morphine  + sufentanil 2 3% 2% 
IT morphine but  
               no IT fentanyl / sufentanil 
2 5% 4% 
Fe
nt
an
yl
 IT Fentanyl  21 75% 63% 
IT fentanyl dose 10–14/ 15-20  µg 18/3   
IT fentanyl but no IT morphine 5 10% 8% 
S
uf
en
ta
ni
l IT Sufentanil  9 20% 16% 
IT sufentanil dose 2.5 / 5/ 5-10  µg 4/4/1   
IT sufentanil but no IT morphine 7 17% 14% 
E
pi
du
ra
l M
or
ph
in
e 
EDA morphine dose    1 / 2 / 4 mg 1/10/1 44% 37% 
EDA Morphine + fentanyl 3 13% 11% 
EDA Morphine  + sufentanil 5 23% 19% 
EDA morphine but  
               no EDA  fentanyl / sufentanil 
4 8% 6% 
Fe
nt
an
yl
 EDA fentanyl                50-100  µg 10 30% 25% 
EDA fentanyl but no EDA morphine 7 17% 14% 
Su
fe
nt
an
il 
EDA sufentanil    5-10/15-25/25-50 µg 11/3/1 47% 39% 
EDA sufentanil but no EDA morphine 10 24% 20% 
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5.1.4  Study IV  
Forty mothers with BMI >30 kg/m2, scheduled for elective CS in spinal anaesthesia were 
invited to participate: 27 mothers consented but four of them had contractions causing early 
acute CS delivery. Among the 23 mothers that were included, 3 polygraphy registrations 
failed. Thus, 20 mothers were included in analysis.  
The mean BMI was 35 ± 4 (30–42), mean age was 35 ± 5 (24–43) years and mean ESS 6 ± 
3 (0–12) with 5 mothers scoring an ESS of <5, 12 scoring an ESS between 5 and 10, and 3 
had an ESS score >10.  
Polygraphic registration: Mean bedtime was 585 minutes (378–818) during the 
polygraphic registration.  
Oxygen saturation: The mean SpO2 registered was 94% ± 1.3 (91–96%). Four mothers 
had mean saturation between 91 and 93%, but no had a mean SpO2 < 91%. The mean nadir 
saturation was 71% ± 10 (49 – 81%).  
AHI was (mean) 6.6 ± 5.2 (0–18.2) “Normal” AHI (<5), was registered in 11 mothers, AHI 
≥5 and <15 was registered in 7 mothers, and 2 mothers had an AHI ≥15 and <30. No 
mother had an AHI ≥30. The mean longest apnoea duration was 30 ± 27 seconds, and mean 
longest hypopnea duration 55 ± 25 seconds. The 2 mothers with high AHI (15.3 and 18.2) 
did not correlate with high ODI or hypercapnia on the TcCO2 registration. 
ODI was (mean) 4.4 ± 3 (0–10.3). “Normal” ODI <5 was registered in 11 mothers, ODI 
between 5 and 10 was registered in 8 mothers, and 1 mother had an ODI of 10.3.  
TcCO2 was (mean) 4.7 ± 0.3 (4.1–5.2) kPa, and mean of max TcCO2 was 5 ± 0.5 kPa. No 
mother had TcCO2 >5.9 kPa.  
We found no correlation between AHI, ODI, BMI and ESS (Figure 12 -15). The Nox device 
showed a correlation between AHI and ODI 0.7 with the ODI providing higher indices, the 
Embletta showed a correlation 0.78 with AHI showing higher indices. 
Routine clinical monitoring did not show any clinical signs or symptoms of severe respiratory 
depression and no mother needed naloxone treatment.  
Pain: During the whole postoperative first day and night, eleven patients had maximum NRS 
4 at movement once, and another three patients maximum NRS 5. At least one episode of 
pain at movement, maximum NRS 4-5 was registered in three patients during postoperative 
hours 0-6 and maximum NRS 8 by one. During the next postoperative hours 6-12, six 
patients experienced pain NRS 4-5 and two patients 6-7. Between postoperative hours 12-21 
seven patients experienced NRS 4-5, one 6-7 and three 8-10 at movement. Rescue pain 
treatment was administered as buprenorphine 0.2 mg to six mothers, and one mother received 
5 mg morphine i.v. 15 h postoperatively; two of those who received rescue pain treatment 
were unable to use NSAID (Table 11). 
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Two mothers, experienced nausea, one was administered metoclopramide.  Light pruritus, 
was experienced by 10 patients, and more severe pruritus by two patients and four mothers 
was treated with clemastine. 
The median discharge time was 49 h; eleven mothers were discharged after 44-53 hours, 5 
mothers after 71-74 hours, one after 82 hours and one mother with preeclampsia and 
infection stayed in hospital for 120 hours. 
Figure 12-15. Values plotted for each mother, no correlation seen. 
 
Figure 12.  AHI (x) and ODI (y)                          Figure 13. ESS (x) and AHI (y) 
          
 
Figure 14. ESS (x) and ODI (y)                            Figure 15. BMI (x) and AHI (y)  
           
 
Table 11. Rescue pain medication administered to the patients Patient	no	 Ibuprofen	400	mg	x	3	 Rescue		Buprenorfin		-	Temgesic®	 Rescue		Morphine	i.v.	6	 No	 0.2	mg	 6	h	+	10	h	postop.	 	7	 Yes	 0.4	mg		 6	h	+	12	h	postop.	 	9	 Yes	 0.2	mg	 6	h	+	15	h	postop.	 	10	 Yes	 0.4	mg		 3	h+9	h+21	h	postop.	 	11	 Yes	 	 	 5	mg	15	h	postop.	14	 Yes		 0.2	mg	 	 	18	 No	 0.4	mg	 3	h	+	18	h	postop.	 	
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5.1.5 Study V 
From 1st of January to October 31st 2016 we identified 150 ECS from the record systems 
but data was only possible to retrieve for 135 cases that were included in analysis.  
For all the 135 ECS the DDI (median) was 17 minutes (range, 5–41). With GA the DDI 
(median) was 10 -13 min shorter compared to SA (DDI 20 min) and tEDA (DDI 23 min) 
respectively (p<0.0005; Table 12). The time to establish adequate anaesthesia accounted for 
the major time difference. The time from anaesthesia start to ready for surgery was 
shortened by 7 and 8 minutes with GA (2 min. range 1-8 min) as compared to SA (9 min, 
range 1-16) and tEDA, 10 min, range 1-23) respectively. Thus the time difference between 
SA and tEDA was 1 min. Different working shifts: daytime, on call during the week and 
weekends did not affect DDI or the separated time events like call to start of anaesthesia, 
start of anaesthesia to surgery, and surgery to delivery. No significant difference was 
observed (Table 13, Figure 16).  
Apgar score of <7 at 5 minutes were registered in 14 neonates: 11/64 neonates with 
mothers having GA, 2/30 that received SA and 1/42 that received tEDA (p < 0.05). pH < 
7.1 were registered in 17 neonates: 14/64 neonates with mothers receiving  GA, 2 /30 
mothers receiving SA (DDI 15 and 17 minutes), and 1/41 mothers receiving tEDA (DDI 24 
minutes). Observation and treatment in neonatal intensive care was provided for 39 
neonates: 22, 10 and 7 that had GA, SA and tEDA, respectively (ns; Table 14 and 15).  
Table 12. Time events for different anaesthetic techniques  
Data are presented in minutes as median (range) 
*** P < 0.0005 vs. regional anaesthesia, ns. No significant difference between SA and tEDA 
GA general anaesthesia, SA Spinal anaesthesia, tEDA top up Epidural anaesthesia, DDI 
Decision to delivery interval 
 
 
  Call - Start 
Anaesthesia 
Start Anaesthesia – 
Ready for Surgery 
Surgery - 
Delivery 
DDI 
GA              
(n = 64) 
6 (1–17) 2 (1–8) 2 (1–4) 10 (5–21)*** 
SA              
(n = 30) 
8 (1–23) 9 (1–16) 3 (1–7) 20 (13–33) ns. 
EDA            
(n = 41) 
8 (1–25) 10 (1–23) 3 (1–8) 23 (12–41) ns. 
ALL             
(n =135) 
6 (1–25) 5 (1–23) 2 (1–8) 17 (5–41) 
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Table 13.Time events for the different work shifts: day time, on call during the week and at 
weekends.  
 Call - Start 
Anaesthesia 
Start Anaesthesia –  
Ready for surgery 
Surgery - 
Delivery 
DDI 
Daytime        (n = 37) 6 (1–25) 7 (1–23) 3 (1–6) 21 (6–41) 
On-call          (n = 60) 6 (1–23) 4 (1–19) 2 (1–7) 14.5 (6–36) 
Weekend       (n = 38) 9 (1–17) 6 (1–17) 2 (1–8) 18 (5–39) 
All                (n = 135) 6 (1–25) 5 (1–23) 2 (1–8) 17 (5–41) 
Data are presented in minutes as median (range) 
 
Figure 16. DDI for ECS studied (n=135) in relation to time of day  
 
* p<0.05 Chi-square test, ns none significant between anaesthetic techniques 
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Table 14. Comparison of anaesthetic technique and neonatal outcome.  
Type of anaesthesia GA (n = 64) SA (n = 30) EDA (n = 41) 
Apgar score at 5 min, median (IQR) 9 (3) 10 (2) 10 (1) 
Apgar score at 5 min.  < 7, n (%) 11 (17) * 2 (7) 1 (2) 
Umbilical cord Arterial, mean:    
     pH 7.13 7.21 7.23 
     pCO2 9.07 7.40 7.28 
     Base Excess -9.53 -6.56 -6.55 
CPAP, n (%) 31 (48) 12 (40) 13 (31) 
Ventilation, n (%) 26 (40) 13 (43) 6 (14) 
Intubation, n (%) 5 (8) 1 (3) 1 (2) 
Neonatal unit, n (%) 22 (34) ns 10 (33) 7 (17) 
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Table 15. CS indications, type of anaesthesia and neonatal pH at birth < 7.1 
CS Indication GA n=64 SA n=30                  EDA n=41 
 number n pH<7.1 number n pH<7.1 number n pH<7.1 
Foetal distress 36 7 16 1 (DDI 15) 32 1 (DDI 24) 
Foetal distress+ placental 
abruption 
    1  
Foetal distress+ breech 
presentation 
    1  
Foetal distress+ uterine 
rupture 
1      
Foetal distress+ placental 
abruption+ 
uterine rupture 
1 1     
Foetal distress+ delivery 
of twins 
1      
Foetal distress+ cord 
prolapse 
1      
Foetal distress + IUGR   1    
Placental abruption 9   2 4 1 (DDI 17)   
Breech presentation 1  4  1  
Uterine rupture  1 1     
Failed vacuum assisted 
delivery 
7 2 5  5  
Cord prolapse 6 1     
Delivery of twins     1  
GA general anaesthesia, SA spinal anaesthesia, EDA epidural anaesthesia, DDI decision – 
delivery time in minutes 
Three SA-CS had DDI longer than 30 minutes, with additional 1-3 minutes, and the neonatal 
outcome was for all three cases 10 for Apgar at 5 min. and pHa 7.21-7.29. 
Seven tEDA-CS had DDI longer than 30 minutes, with additional 1-11 minutes, with the 
neonatal outcome for Apgar at 5 min. 9 for one, and 10 for the other six, and median pHa 
7.22 within range 7.13-7.29. 
 
5.2 TABLES - REFERENCES OF INTRATHECAL ANAESTHESIA                        
IN LABOUR AND ABDOMINAL HYSTERECTOMY 
In order to put study I and II in perspective I have listed them with references, including 
methods, different doses used and most important results in table 16 – labour analgesia and 
17 – abdominal hysterectomy for overview. 
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5.2.1 Table 16. References listed for labour spinal analgesia 
SA spinal analgesia, EDA epidural, CSE combined spinal epidural                                                                           
M morphine, F fentanyl, S sufentanil, B bupivacaine, diff d different doses, vs. versus 
Reference  Method 
Labour 
analgesia 
ITM µg 
(n) 
ITother 
opioid µg   
(n) 
IT local 
anaesthetics 
and other 
Results 
 
Scott PV 
et al. (32) 
1980 
SA 
M 
1500 
(12) 
 
No No 1st stage No pain/ 2nd stage 4 pt no pain+3 pt  
less pain. Itching (face), nausea and vomiting,  
frontal headache;  CS: 3pt, Forceps: 3pt   
Baraka A 
et al. (33) 
1981 
SA 
M diff. d. 
I 1000 
(7) 
II2000 
(13) 
No No Onset:  15 -60 min; Duration: 8-11 h 
Majority: Somnolence, nausea, vomiting, itching 
Abboud 
TK et al. 
(6) 1984 
SA 
M diff. d. 
I  500  
(12) 
II 1000   
(18) 
No No 93%: at least 50% pain relief.  
Onset:  15-60 min after inj. Duration: 6-8 h 
80% pruritus, 53%, nausea or vomiting, or both; 
43%, urinary ret.   43% drowsiness 
Leighton 
BL et al. 
(58) 1989 
SA 
MF 
250 (15) Fentanyl  
25 
No Onset:  5 min after injection  
Duration (n): Comfortable:  (9): Spontaneous 
labour: 187±148(6) + Oxytocin ind.: 222±196 
(3) EDA required (6): Spontaneous labour: 
145(1) + Oxytocin ind: 139±57 (5) 
Abouleish 
E et al.(59) 
1991 
SA M vs  
EDA B vs  
CSE MB 
 
I  200 
(20) 
II   0   
(22) 
III 200 
(20) 
No I   0 
II  & III EDA 
0.125% 10ml 
Bupivacaine  
 
Neither ITM 0.2 mg nor 10 ml 0.125% epidural 
bupivacaine produced effective adequate pain 
relief in labour, CSE MB produced excellent 
analgesia. ITM sign. reduced the dosage 
requirement of epidural bupivacaine. Nausea, 
vomiting, and pruritus were sign. greater in M 
groups 
Grieco et 
al. (60) 
1993 
SA  
S   vs  
S+ 
Epinephri
ne  
vs MS  
III  250 I & II & III 
Sufentanil 
10 
No local 
anesthesia but 
II Epinephrine 
250µg 
Onset: 5 min after injection similar in all groups 
Duration(n): I(12) 115 ±40 / II(13) 132 ±45 / 
III(14)135 ±37 
Most significant side effects was seen in 
morphine group – pruritus and nausea  
Bloodpressure decreased 5 min after it inj. – no 
diff. btw groups 
Herpolshei
mer A (61) 
1994 
SA  
MF vs  
controls 
I   250 
(75) 
 
II   0  
I Fentanyl  
25 
II 0  
No SA:  a satisfactory level of pain relief without 
disrupting the normal course of labour 
pruritus (81.3%), urinary reten. (53.3%), nausea 
and vomiting (44.0%). Headaches (9.3%),  
respiratory depr (1.3%)  oversedation (1.3%) 
Campbell 
DC et al. 
(62) 1995 
SA  
B vs  
S vs  
SB 
No  I 0  (14) 
 
II  & III 
Sufentanil  
II  10 (14) 
III 10 (15) 
I  Bupivacaine 
2.5mg 
II 0 
 
III  
Bupivacaine 
2.5mg 
I  Duration: 70 ± 34 min,  VAS: More than II & 
III 
II Duration:114± 26 min, VAS: More than III 
beyond 75 min 
III Duration:148 ± 27 min,  VAS: Lowest;  Sign. 
prolonged labour analgesia without adverse 
maternal or foetal effects. 
Hypotension: not in the S gr; occurred 
transiently in the two bupivacaine groups (P < 
0.09). 
Viscomi 
CM et al. 
(63) 1997 
SA SB  
Early vs 
advanced  
Labour  
No  I & II 
Sufentanil 
10 
 
I & II 
Bupivacaine 
2.5mg 
 
Duration:     I  cx 3-5 cm (18): 163 ± 57 min ;  
II cx 7-10 cm (23): 120 ± 26 min    p<0.01 
cervical dilation and stage of labour significantly 
impact the effective duration 
Asokumar 
B et al. 
(64) 1998 
SA  
F vs B vs 
FB 
No I & III 
Fentanyl 
25 
II   0 
I   0 
II & III 
Bupivacaine 
2.5mg 
Duration: I-F 62.5, II-B 55.0, III-F+B 94.5 min, 
longest in F+B group and a more rapid onset 
compared with either drug alone. 
Palmer 
CM et al. 
(65) 1999 
SA  
F  diff. d. 
7 groups 
n=12 in 
each 
group 
No Fentanyl  
I      5 
II   10 
III  15 
IV  20 
V   25  
VI  35 
VII 45  
No Rapid, profound labour analgesia with minimal 
side effects.  
Duration: increased to 89 min with increasing 
dose up to 25 µg. There is little benefit of 
increasing the dose beyond 25 µg.  
No diff. among groups regarding pruritus. 
Nausea and vomiting were uncommon.  
FHR did not change after inj. 
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Reference Method ITM ITother o. IT la/other Results 
Norris MC 
et al. (5) 
1998 
SA  
S  diff. d. 
 
No I  & II 
Sufentanil I   
5  (32)  
II 10 (31) 
 
No I & II: Adequate analgesia. 10µg sufentanil: 
slightly more profound analgesia, Duration: no 
diff. between the groups.  I & II: significant 
increases in itching and end-tidal CO2; 10µg 
dose: more sedation and decrease in SaO2. 
Gautier 
PE et al. 
(66) 1998 
SA 
S vs 2S vs 
C vs 2C 
vs SC vs 
2SC 
(98) 
No I+V 
Sufentanil 
2.5 
II+IV 
Sufentanil 
5 
III+V 
Clonidine 15 
µg 
IV+VI 
Clonidine 30 
µg 
Group Voch VI (Sufentanil 2.5 µg+Clonidine 30 
µg) and (Sufentanil 5 µg+ Clonidine 30 µg) had 
longer duration 145±36 /±45 vs 104 ±35 for 
sufentanil alone. No adverse events registered. 
Palmer 
CM et al. 
(65) 1999 
SA  
F vs FB vs 
F2B 
B diff. d. 
No I   & II & 
III  
Fentanyl 
25 
I      0 
II  & III 
Bupivacaine 
II  1.25 mg 
III 2.5 mg 
I   (30)                             Duration: 92 ± 23 min  
II  (30) Onset: faster;      Duration  94 ± 25 min 
III (30) Onset : Fastest;  Duration 108 ± 20 min 
was longer 
No differences btw groups in pruritus or 
bloodpressure 
Sia AT  
et al. (55) 
1999 
SA  
2S2B vs  
SB 
diff. d. of  
S and B 
No  I 
Sufentanil 
10  
II 
Sufentanil 
5  
I  Bupivacaine 
2.5 mg 
II  
Bupivacaine 
1.25 mg 
I  lasted longer than II    
I:  had lower VAS for the first 5 min (P < 0.05) 
and a higher level of sensory blockade (median 
of T4 compared with T7 in II; P < 0.01) 
hypotension I - 9 pt vs II - 2 ;P < 0.05, a greater 
degree of motor block (P < 0.05), and a higher 
incidence of sedation I - 9pt vs    II -1; P < 0.01. 
Cheng CJ 
et al. (67) 
2001 
SA  
SB vs FB 
No I  
Sufentanil 
5  
II Fentanyl 
25  
I  & II  
Bupivacaine 
1.25 mg 
 
No significant difference in the duration: 
I   118 ± 54 min vs  II  109 ±  49 min 
Group II had a more rapid onset (P<0.05)  and a 
higher cephalad block (median T4 vs T7, first 30 
min after the block.  
Yeh HM 
et al. (34) 
2001 
SA  
FB vs 
MFB 
I   0 
II  150  
I  & II  
Fentanyl 
25  
  
I  & II 
Bupivacaine 
2.5 mg 
Duration (n):     I FB     (48)  - 148 ± 44 min vs   
                         II MFB (47)  - 252 ± 63 min      
p<0.05   
Adverse effects:  no sign. Differences   
Eriksson 
SL et al. 
(68) 2003 
SA  
SB 
No Sufentanil  
7.5 (40) 
Bupivacaine 
2.0 mg 
Onset & duration: VAS at 5, 15, 30, 60, 90, 120 
and 150 min were 1.5, 0.5, 0, 1, 1.5, 2 and 3 
respectively. 77% scored analgesic quality as 
excellent.  Hypotension: 6 pt, FHR -disturbances 
4 pt, Motor block, sedation and nausea were 
rare. Pruritus: 85%  
Hess PE  
et al. (69) 
2003 
SA  
FB vs 
MFB 
I    0 
II  125    
I  & II   
Fentanyl   
12.5 
 
I  & II   
Bupivacaine 
2.0 mg 
 
Duration: similar between groups (89 min vs 84 
min: only 20% of MBF  experienced prolonged 
analgesia. During subsequent epidural analgesia, 
MBF had sign. lesser rate of breakthrough pain 
Viitanen H 
et al. (70) 
2005 
SA  
FB 
No Fentanyl 
25   (209) 
 
Bupivacaine 
2.5mg 
Duration: 101 ±34 min;  Pain relief:  excellent -
65%, moderate -20%,  inadequate - 14%,  26% 
pt got additional analgesia  ( 18% - VAS >3 at 
20 min after spinal inj. and  8% - spinal block 
wore off before delivery) 
Vasudevan 
A et al. 
(71) 2007 
SA  
FB vs 
MFB 
I    0 
II  100    
I   & II   
Fentanyl  
12.5 
I & II  
Bupivacaine 
2.0 mg 
MFB had a significantly lower rate of 
breakthrough pain than the FB group [0.6 (0.6) 
vs 1.1 (0.8) episodes per pt; P<0.01]  and longer 
time to first episode of breakthrough pain (300 
vs 180 min) 
Kuczkows
ki K et al. 
(72) 2008 
SA 
BMC 
No  
compare 
250 
(62) 
0 Bupivacaine 
2.5 mg  
Clonidine 45 
µg 
Maternal satisfaction 81% very satisfied +11% 
satisfied. Mean painVAS 30min-3 h: 3.3-3.9, 4h-
12h: 4.1-5.9; Nausea 9.6%, occasional shivering, 
6.5%, pruritus, 8%. No respiratory depression, 
hypotension or foetal complications. 
Hein A  
et al.  
study I 
2010 
SA  
SB vs 
MSB 
M diff. d. 
I    0 
II   50 
III 100 
I  & II  & 
III 
Sufentanil 
5 
I  & II & III 
Bupivacaine 
1.25 mg 
 
Duration: similar between groups, no sign 
differences regarding onset, or side effects.  
Anabah T 
et al. (73) 
2015 
SA 
MFB 
No  
compare 
200 
(328) 
Fentanyl 
25 
Bupivacaine 
2.5 mg 
98.8% mild-no pain, 1.2% moderate pain;  
87.7% no effect on ambulation, 12.3% mild 
effect; 31.3% pruritus, 26.8% nausea, 3.9% both 
pruritus + nausea; 14.5% required naloxone treat 
pruritus/nausea or both; 3.6% foetal bradycardia  
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5.2.2 Table 17 References listed for intrathecal anaesthesia for abdominal 
hysterectomy 
Reference  Method ITM 
µg/ µg/kg 
Intrathecal 
other drug 
And 
GA 
Vs.  
GA 
Results 
Yamaguchi 
H et al.(74) 
1989 
SA 
tetracain + 
M diff. d 
0 / 30 / 
40 / 60  / 
80 /100  
hb tetracaine 
12-14 mg 
No No  SA: 40-80 µg M + tetracaine 
made po iv narcotics 
unnecessary in 60-70% for 24 
h and minimal adverse effects 
Sarma VJ 
et al. (9) 
1993 
GA vs 
GA+ 
Postop SA  
M diff d 
      0  
   / 100  
   / 300  
   / 500  
0 GA- 
inhal. 
GA- 
inhal. 
SA: M 0.1, 0.3, 0.5: Lower 
VAS vs. GA; M 0.3 & 0.5 at 
10 h- lower VAS vs. 0.1; 
VAS: No diff 0.3 – 0.5 Nausea 
& vomiting most in GA, 
lowest in 0.3; Pruritus most in 
M-groups, most in 0.5 
Karaman S 
et al. (75) 
2006 
GA vs   
GA+ SA  
M 
5 µg/kg 0 GA- 
inhal. 
GA- 
inhal. 
SA: Lower(sign) VAS po, 
Less PCA M-consumption,  
lower stressresponse  
Vaida SJ  
et al. (56) 
2000 
GA vs  
GA+ SA  
B 
No 12 mg hb 
bupivacaine 
GA- 
inhal. 
GA- 
inhal. 
SA: Lower VAS 2 h po 
Similar VAS 4-24 h po 
Less PCA M-consumption 
Wang JJ  
et al. (8) 
1996 
GA vs SA 
B 
No 15 mg hb 
bupivacaine 
No GA- 
inhal. 
SA: Lower VASrest 6-24 h po 
Lower VAScough 6-30 h po 
Less M-consumption 0-24 h 
Massicotte 
L et al. (76) 
2009 
GA vs SA 
+ sed 
MFB 
150  15 mg hb 
bupivacaine + 
fentanyl 15 µg  
No GA- 
inhal. 
SA: Lower VASrest -18 h po, 
Lower VASstress-48 h; Less 
PCA M-consumption. Shorter 
PACU & hospital stay 
Sprung J  
et al. (77) 
2006 
SA  
vs  GA 
2 µg/kg, 
max 200 
µg 
15 mg hb 
bupivacaine + 
clonidine 1 
µg/kg  
No GA- 
inhal. 
SA: Lower VAS 0-14 h 
SA: Lower pain 2 weeks po 
No differences SA vs. GA at 
12 weeks 
Kroon UB 
et al. (78) 
2010 
 
SA + 
TIVA 
vs  GA 
100  15 mg hb 
bupivacaine  
GA-
TIVA 
GA- 
inhal. 
SA+ TIVA: shorter po ward 
180 vs 237 min, shorter 
hospital stay 2 vs 3 days, less 
nausea  
Borendal 
Wodlin N 
et al. (79) 
2011 
SA + sed. 
vs  GA 
200 µg  20 mg hb 
bupivacaine  
No GA- 
TIVA 
SA: Less M-consumption 0-24 
h, faster recovery of bowel 
function. SA groups: more 
Pruritus and vomiting  
Hein A  
et al.  
study II 
2012 
SA + GA 
M diff d 
       0  
   / 100  
   / 200  
   / 300  
12 mg hb 
bupivacaine 
GA 
inhal. 
 SA: M groups: less total iv M-
consumption 0-24 h po, least 
in 200 µg. Lower VASrest 0-
12 h po Pruritus only in ITM-
groups. Emesis similar in all 
groups 
SA spinal analgesia, GA general anaesthesia, GA inhal. general anaesthesia inhalational, TIVA total intraveno,us 
anaesthesia, sed. sedation, vs versus, M morphine, F fentanyl, B bupivacaine, hb hyperbaric, IT intrathecal, iv 
intravenous, po postoperative, diff d. different doses, PCA patient control analgesia, PACU postanaesthesia care 
unit 
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6  DISCUSSION 
6.1 STUDY I AND II 
This thesis has its focus on pain management in the female patient, pain associated with 
childbirth, CS or hysterectomy. We studied the effects of addition of different low doses of 
ITM to fixed doses of local anaesthesia and in the first study a fixed dose of fast acting opioid 
as well. We studied analgesia for different mechanism of pain; in study I – during labour with 
primary outcome duration of analgesia and study II – post abdominal hysterectomy pain, with 
primary outcome need of additional analgesics. In study I we did not find any clinically 
relevant effect of adding 50 or 100 µg of ITM for analgesia in established labour with regard 
to lengths of analgesia. In study II however we found addition of ITM associated with 
reduced accumulated 24 hours post-operative morphine consumption in all three morphine 
groups 100, 200 and 300 µg and the opioid sparing effect seemed to plateau at 200 µg. 
Patients receiving ITM scored lower VAS pain at rest postoperatively the first 12 hours, but 
no difference regarding number of patients with VAS pain > 4 was seen.  
6.1.1 Power analyses 
We believe the studies were correctly powered. In our placebo group regarding study I the 
duration of effective analgesia (60-240 min) was in line with what we expected from other 
studies using similar doses of bupivacaine and sufentanil (55, 67). The placebo morphine 
consumption in study II was in the same magnitude with what was anticipated in the power-
analysis (8). 
6.1.2 Patient demographics and basal data influencing experienced pain 
In both studies we were aiming for homogenous groups regarding severity of pain. Regarding 
study I we selected nulliparous women with a cervical dilatation at recruitment of 3-7 cm. 
Cervical dilatation is known to influence grade of pain and the chosen range may be wide 
(63). However no differences regarding onset time and duration were detected when directly 
comparing women with an initial dilatation of either 3-5 or 6-7 cm. Regarding study II we 
registered operation time, blood loss and type of tumours and find the groups comparable.   
6.1.3 Pain-rating 
We defined experienced pain as VAS > 4. One might argue that this is high but it was at the 
time in accordance with the routines of our departments. It is unlikely to have affected any 
potential difference on duration of analgesia or the morphine consumption respectively 
between the study groups. Pain at rest was overall well controlled in both studies.  
6.2 INTRATHECAL MORPHINE IN LABOUR 
In labour, epidural analgesia is shown to give the most effective pain relief (4). Spinal labour 
analgesia with varying mixture of local anaesthetics and different opioids has shown to 
produce effective labour analgesia, with the advantages of being easier, faster and of less cost 
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to administer but with limitation of restricted duration (80). When pencil point shaped 
needles of small sizes are used and small volumes of drugs are injected the risk of 
complication with spinal labour analgesia seems even less than with labour epidurals. 
Morphine in doses 0.25 – 2 mg has previously been shown to produce excellent labour 
analgesia but with high frequency of side effects (Table 16)(6, 33, 61). Yeh et al. found a 
combination of bupivacaine 2.5 mg, fentanyl 25 µg and low dose of morphine, 150 µg ITM 
to reach duration of 252 min. vs. 148 min. without ITM, and observed no difference 
regarding side effects (34). This is a notable extension of the duration of clinical value. Our 
aim was to study if reduced dose of ITM in a spinal mixture would prolong duration of labour 
analgesia. In CS anaesthesia low doses have been proven efficient for postoperative pain 
relief (38). We used a low dose basic regime for all groups, 1.25 mg bupivacaine + sufentanil 
5 µg, with a previously shown shorter duration (120 min) than with doubled doses (164 min) 
but also less adverse effects (55). Still we believe this mixture lasted long enough, 60 – 240 
minutes in our placebo group, for the onset of ITM component, since peak analgesic effect 
for ITM is reached within 30-60 minutes (34, 81). The patients had an epidural catheter to use 
on demand (administered by the midwife) when pain returned after spinal analgesia waned. 
Apart from duration of analgesia, we analysed mean hourly consumption of epidural 
bupivacaine and sufentanil and found no differences between the groups. This indicates that 
there neither was a more prolonged analgesic effect of the addition of morphine in our study. 
As table 16 shows there are only, two other to us known studies, exploring effects of ITM in 
doses of less than 150 µg. In accordance to our study addition of 125 µg ITM to bupivacaine 
2 mg and fentanyl 12.5 µg did not prolong the duration of spinal labour analgesia, but Hess et 
al. observed reduction in breakthrough pain during continued labour and less need for 
analgesia first 24 hours after delivery (69). This is in line with observations of Vasudevan et 
al. who used the same basal mixture but with supplementation of 100 µg of ITM in a CSE 
with immediate start of continuous epidural infusion of bupivacaine/fentanyl after spinal 
injection (69, 71). However we did not follow our patients regarding breakthrough pain 
during continued labour after spinal duration had waned off, or the amount of consumed 
rescue analgesia after delivery, which is a weakness in our study. Severe, acute pain after 
vaginal delivery has been found in 1 of 13 women, and is the most important risk factor for 
developing persistent pain after childbirth (18). Mac Arthur et al. administered 2.5 mg of 
epidural morphine after vaginal delivery before labour epidural catheter was removed and 
found a 78% reduction in analgesic requirements (82). However we are not able to say 
whether addition of 50 or 100 µg ITM affected acute pain after vaginal delivery, or in a 
longer perspective, persistent pain weeks after delivery, but this is an interesting aspect for 
future studies.  
In study III we found ITM for single spinal labour analgesia was not practiced in Sweden. 
This is not surprising since in Sweden there are good opportunities, for mothers that request 
pain relief during delivery, to get an epidural in every delivery department. Epidural analgesia 
is provided to 35 % among all deliveries in Sweden and 52 % among nulliparous women 
(54). Single spinal analgesia with opioid mixture recommended, bupivacaine 1.5-2 mg and 
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sufentanil 5 µg, is used to a much lesser extent, primarily to women when there is a fast 
progression and delivery is expected soon, within 60-90 minutes. Another indication for 
spinal analgesia may be when a woman is in so much pain that she cannot cooperate during 
the procedure of epidural administration, but this can be offered after first pain relief is 
conducted with a single spinal. Epidural analgesia is more expensive, time and resource 
consuming, but with the advantage of no restriction regarding duration. In addition, it has the 
possibility to use in case of caesarean section even in the emergent cases as shown in study 
V. However in low income, developing countries there are restricted opportunities to offer 
pain relief to delivering mothers at all. Still management of labour pain is regarded as a 
fundamental human right by WHO (83). There are reports from Indonesia and Ghana where 
single spinal analgesia has been used in this context (Table 16)(72, 73). Bupivacaine 2.5 mg 
is used as basic local anaesthetic in both studies, Kuczkowski et al. added Clonidine 45 µg 
and 250 µg of morphine and Anabah et al. used Fentanyl 25 µg and 200 µg of ITM as 
supplement to bupivacaine (72, 73). Both report sufficient pain relief to a large extent, 
maternal satisfaction rated very satisfied or satisfied in 92% and mild or no pain in 98.8% 
respectively. Information about duration was not shown in hours or minutes but Kuczkowski 
et al. reported reduced VAS pain <6, even after 12 hours (Table 16)(72). Clonidine has been 
described associated with high incidence of maternal hypotension, sedation and foetal heart 
rate abnormalities (84, 85). However Kuczkowski et al. found no serious advert events and 
reported low incidences of side effects, pruritus 8% and nausea 9.6% (72). Higher incidences 
of side effects was found by Anabah et al.; foetal bradycardia was seen in 3.6%, treatment 
with naloxone was needed in 14.5% for pruritus/ nausea or both (73). In the context of low 
income country, choosing between pain relief with longer duration and side effects women 
probably prefer less pain in accordance with mothers rating of side effects observed for 
caesarean sections (86). Carvalho et al. found pain during and after CS highest ranked of 
avoidable outcomes followed by vomiting, nausea, cramping and itching (86). Side effects of 
ITM supplementation during labour analgesia are hard to separate from the side effects from 
included lipid soluble (“fast”) opioids like pruritus, and experienced effects from delivery, 
like nausea and vomiting. As long as serious side effects like FHR abnormalities and 
maternal respiratory depression and hypotension can be avoided and carefully observed and 
treated, addition of a morphine dose of 150-200 µg seems reasonable (80, 87).  
6.3 INTRATHECAL MORPHINE IN ABDOMINAL HYSTERECTOMY 
 
The role of good pain relief both in the acute postoperative period, to enhance a fast recovery 
process, but also in a longer perspective, in order to reduce persistent postoperative pain and 
anxiety, is today rather well established (13, 88, 89). However the routines, how to gain good 
targeted pain relief, vary and are under discussion, but to aim for opioid sparing and use a 
multi model and individualized approach is not controversial even though not always 
implemented (90). Fast mobilisation to avoid thrombosis, lung secret problems and bowel 
problems with constipation and pain from paralytic ileus requires a pain free or low pain- 
situation (91). Spinal anaesthesia has been used, in order to minimise postoperative pain and 
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morphine consumption in this concept with different approaches; after or more often before 
surgery, different drugs and doses, aiming for a mixture with minimal side effects and still 
long duration of effective pain relief (Table 17)(9, 56, 75-77, 91). Sarma et al. and Karaman 
et al. compared general anaesthesia with general anaesthesia together with sole spinal 
morphine anaesthesia (9, 75). Vaida et al. and Wang et al. provided bupivacaine spinal 
anaesthesia to one group and compared with general anaesthesia, given to both groups and 
the other group respectively (8, 56). Massicotte et al., Sprung et al., Kroon et al. and 
Borendahl-Wodlin et al. administered a mixture of spinal bupivacaine 15-20 mg and ITM; 
100-200 µg and fentanyl for one study (Massicotte et al.) and clonidine for another (Sprung et 
al.) study (76-79). The spinal groups were sedated or in the study by Kroon et al. they had 
TIVA and were compared to general inhalational anaesthesia. Most of the studies assessed 
postoperative morphine consumption, which was found reduced for SA-groups and /or VAS 
pain, which also was found reduced. Earlier studies assessed for shorter perspective; first 24 
postoperative hours, while studies comparing spinal anaesthesia versus general anaesthesia 
performed later years have a more protracted and broader perspective, also evaluating start of 
per oral fluid, removal of indwelling catheter, bowel function, and length of hospital stay. We 
only followed the patients the first 24 postoperative hours and did not apply a broader view of 
postoperative recover, nor did we explore occurrence of persistent pain, which is a limitation. 
We aimed to explore if one of the three commonly used doses of ITM; 100, 200 or 300 µg 
was more beneficial than the others, weighing benefits-risks. Our findings imply that there 
are less postoperative morphine consumption and pain with supplementation of any of these 
doses morphine, but no extra benefit in doses higher than 200 µg of ITM. First postoperative 
hours results of morphine consumption and pain rating may have been influenced by the 
injection of intravenous morphine, given to all patients before extubation, to ensure sufficient 
pain relief in all groups. We did not include a lipophilic opioid, e.g. fentanyl 10-20 µg or 
sufentanil 2.5-5 µg as is recommended in CS spinal anaesthesia and as for hysterectomy 
spinals, is established routine in our department at present, but we did not want another 
opioid to interfere with our findings about ITM (92). For CS spinal anaesthesia, patients are 
awake and have increased risk of experiencing pain, nausea and/ or vomiting without fentanyl 
supplementation intraoperative, but no meaningful postoperative analgesia is found with 
doses commonly recommended (92-94). All our patients had spinal anaesthesia and general 
anaesthesia with increasing doses of morphine as the only varying factor.  
When comparing side effects we found no serious adverse events, pruritus was only 
occurring in morphine groups, nausea was not uncommon, but without differences between 
groups. Sevoflurane nitrous oxide general anaesthesia was used in all groups and may have 
influenced this; more nausea was found in general anaesthesia group compared with spinal 
morphine anaesthesia group by Kroon et al. (78). In opposite to those findings Borendahl-
Wodlin et al. found more vomiting day of surgery in spinal anaesthesia group having 20 mg 
bupivacaine with 200 µg morphine complemented with propofol-sedation (79).  
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Our patients got paracetamol regularly but no NSAID, which has been shown to decrease 
additional morphine requirements in abdominal surgery and is strongly recommended 
together with paracetamol on regular basis (95, 96). NSAID were excluded from our protocol 
since sensitivity is not uncommon and might have been unequally distributed among the 
groups and thereby interfering with results. Preemptive administration of gabapentin has 
become popular, in order to prevent neuropathic pain, as it antagonizes N-methyl-d-aspartate 
receptor (97). Alayed et al. found in their review gabapentin to decrease postoperative pain 
scores, narcotic consumption, nausea, and vomiting but they excluded studies in which 
local or regional anaesthesia was performed (97). Kiatchai et al. concluded that a 
preoperative dose of pregabalin 150 mg, antagonising NMDA receptor, did not affect pain 
score or morphine consumption when abdominal hysterectomy was performed in spinal 
anaesthesia with hyperbaric bupivacaine and 200 µg morphine (98).  
Spinal anaesthesia including local anaesthetic and ITM in dose range of 200 µg is 
recommended in open general gynaecologic surgery in a multimodal and opiate sparing 
strategy in the guidelines for gynaecologic surgery by Enhanced Recovery After Surgery 
(ERAS®) Society (96). Nelson et al. list benefits like reduced pain and morphine 
consumption, reduced risk of post-operative ileus, peri-operative stress hormone release 
and improved recovery with less drowsiness, but with the expense of more pruritus (96). 
Spinal anaesthesia with 20 mg hyperbaric bupivacaine and 200 µg morphine and propofol 
sedation was also found more cost-effective than general anaesthesia in abdominal 
hysterectomy by Borendal Wodlin et al.(99). 
In study III we find 20/32 answering units using spinal with addition of ITM for 
gynaecological operations, mainly hysterectomies, with a variety of dosing spread between 
80 and 200 µg, 9/20 using 200 µg dose.  
TAP-block is recommended as an alternative if spinal or thoracic epidural is not performed 
(96). In CS it has been concluded TAP-block is associated with greater postoperative 
morphine consumption and higher pain scores than ITM but fewer side- effects (100). We 
find, in agreement with the writer, TAP-block a reasonable alternative when ITM is not 
used in open gynaecological or obstetric surgery, like after sole general anaesthesia or when 
contraindicated or as rescue if pain relief provided by ITM is insufficient (96, 100). 
Addition of dexamethason 8 mg to 20 ml bupivacaine 0.25% for TAP prolonged duration 
of analgesia and reduced morphine requirements 48 postoperative h. after abdominal 
hysterectomy performed in general isoflurane anaesthesia, in a study by Ammar et al. with 
lower incidence of nausea and vomiting (101).  
Different surgery methods/approaches have impact on following pain and pain treatment 
(102). Laparoscopic surgery and robot assisted laparoscopic surgery is increasing and little 
is known about whether these patients gain benefits from ITM and if so what doses should 
we use? From laparoscopic colon surgery, pre induction spinal, with a mixture of 
bupivacaine and diamorphine is known to reduce the stress response and post-operative 
morphine consumption compared with morphine-PCA based post-operative analgesia 
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(103). Koning et al. investigated the role of spinal with ITM 240-300 µg depending on age 
and bupivacaine 12.5 mg in laparoscopic colon surgery within an ERAS program, and their 
findings about ITM spinal, providing faster and less painful recovery, is just recently 
published (104). Segal et al. studied robotic gynaecologic surgery; sacrocervicopexy with 
subtotal hysterectomy, and found general and spinal anaesthesia providing significantly 
lower pain score, less analgesic use and increased patient and nursing staff satisfaction 
compared with general anaesthesia alone (105). The intrathecal injection included fentanyl 
15 µg and morphine 0.15–0.5 mg, 3 µg/kg, a rather high morphine dose with regards to our 
findings, with no further benefits with ITM more than 200 µg (105). Arguments in favour 
of spinals with ITM, compared with thoracic epidurals, are easier handling, easier and 
earlier mobilizing and shorter hospital stay (103).  
6.4 NEUROAXIAL MORPHINE IN CAESAREAN SECTION 
6.4.1 Spinal anaesthesia  
Today the majority of CS are performed in spinal opioid anaesthesia, which is regarded 
“golden standard” in absence of a working labour epidural to top up, described in ECS in 
study V (39-41). There are good evidence and recommendations, to use a mixture of local 
anaesthesia – commonly used hyperbaric bupivacaine 0.5%, with both lipophilic, fast action 
opioid, and hydrophilic, slow action opioid, to gain peri- and postoperative advantages (39, 
40, 92-94, 106). Quality of CS spinal block is improved and volume of local anaesthesia can 
be reduced with supplementation of fentanyl 10-25 µg or sufentanil 2.5 or 5 µg resulting in 
less side effects from local anaesthetics, reduced need of perioperative analgesic 
supplementation, less nausea and more prolongation of analgesia in sufentanil 5 µg group, 
but to the expense of more pruritus mainly seen in sufentanil groups (92, 94). There are 
findings implying risk of acute opioid tolerance, caused by fentanyl diminishing the effect of 
ITM, since higher postoperative pain scores have been found when fentanyl is added to 
bupivacaine/morphine mixture (107). This is however not clarified, and the reduction of 
patients having intraoperative pain and requirement for intraoperative rescue medication must 
not be overlooked (94).  
In UK diamorphine is used as adjunct to bupivacaine, having physiochemical properties 
resulting in fast onset of analgesia, as well as prolonged duration of analgesia due to high 
lipophilicity (octanol-water coefficient 280) and the active metabolite; morphine, providing 
the extended duration of analgesia (40). Diamorphine is not available in Sweden, but we 
found in study III majority of obstetric anaesthesia departments use a mixture of bupivacaine, 
fentanyl 10-20 µg or sufentanil 2.5-10 µg and morphine 100-125 µg as is recommended as 
“golden standard” for spinal CS anaesthesia. All 32 answering units used at least one 
intrathecal opioid but 14 of these units used sole one, lipo- or hydrophilic opioid as adjunct to 
bupivacaine; 2 units use sole ITM, 5 units use fentanyl and 7 units use only sufentanil (Table 
10). When assessing the impact of different routines with respect to total performed CS in the 
obstetric anaesthesia units we found one-intrathecal-opioid-units representing 26% of 
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performed CS in Sweden, 55% supplementing bupivacaine with ITM and fentanyl and 2 % 
with ITM and sufentanil (Table 10, Figure 11). The rest 17% did not reply the questionnaire.  
A few units in our study replied use of ITM only in elective situations. The rational for this is 
unclear and the literature support use of both a lipophilic opioid and ITM in emergent CS, 
even the most emergent situations as we studied in study V (40, 41). SA median time for DDI 
was 20 minutes with range between 13 minutes and 33 min. Three SA-CS exceeded the 30 
minutes rule but with additional 1-3 minutes and the neonatal outcome was for all three cases 
10 for Apgar at 5 min. and pHa 7.21-7.29. 
There is higher risk of intraoperative pain and need of rescue medication during ECS both 
with spinal and epidural anaesthesia compared with elective CS (108). Addition of a 
lipophilic opioid will contribute to a shorter onset, thus time from decision to incision, and 
less risk of pain problems during the delivery, and thereby may reduce need of conversion to 
general anaesthesia (40, 108). There are arguments of time loss and risk of dosing-errors 
when mixture of several drugs is performed, which is to be considered. However the 
evidences of risk-benefits are in favour of adding a lipophilic opioid, producing an earlier 
onset and more profound anaesthesia, in the most emergent cases in accordance with our 
results in study V (24, 40, 41). Ngan et al. proposed a synergistic effect with intrathecal 
opioid-supplementation to local anaesthetics after study in labour (109). 
A dose of 100 µg ITM is recommended in addition, as the hydrophilic opioid, prolongs the 
duration of post-operative analgesia, not provided by fentanyl and sufentanil (39, 40, 93, 
106). ITM is very efficient decreasing pain and requirement of supplemental anaesthesia after 
abdominal surgery, and shown superior to oral and intravenous morphine and local 
anaesthetic techniques like TAP and wound infiltration (39, 100, 110). Severe post-operative 
pain after CS will contribute to, in addition to the discomfort, difficulties in mobilizing, 
causing thromboembolic risks and risks of ileus but is also a recognised risk factor for 
persistent pain (1, 2, 18).  
6.4.2 Epidural anaesthesia 
Epidural anaesthesia for CS is today usually chosen when there is a labour epidural in place 
to top up or in special cases in a CSE, when prolonged surgery is expected. Top up of labour 
epidural has been proven as fast as general and spinal anaesthesia (40, 41). We found in study 
V, GA faster than both SA and tEDA (10-13 minutes respectively) but with no statistical 
differences comparing SA and tEDA. We use a mixture of ropivacaine 0.75% 15-20 ml with 
supplementation of fentanyl 50-100 µg. Parate et al. found supplementation to bupivacaine 
0.5% with 50 µg fentanyl providing significantly intraoperative reduction of pain, and rescue 
analgesic requirements with prolonged analgesia, and it is recommended to add a dose 
lipophilic opioid to local anaesthesia in a top up mixture (40, 111). In opposite to this 
Malhotra et al. found no benefits with addition of fentanyl 75 µg to epidural levobupivacaine, 
when extending labour epidural for elective CS (112). All the labour epidurals were 
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maintained with midwife administered boluses; 10-15 ml of bupivacaine 0.1% plus fentanyl 2 
µg/ml as required up to half-hourly (112). 
For epidural top up, different local analgesic mixtures have shown significant differences 
regarding onset of anaesthesia; Allam et al. halved the onset time with fresh mixture of 
lidocaine-bicarbonate-adrenaline compared with levobupivacaine to 7 (5-8) min. and 11 (9-
14) min. respectively, with side effect of increased maternal sedation (113). Sodium 
bicarbonate is thought to facilitate passage across the neuronal membrane of lignocaine, with 
its low pKa. No additional lipophilic opioid was used to extend to surgical anaesthesia, and 
labour analgesia was maintained with bupivacaine 0.1% and fentanyl 2 µg/ml as 3 ml/h 
background infusion plus 5 ml boluses; 15 min. lockout-time in PCA (113). They conclude 
there are so many differences in studies; speed and volume of top up injection, definition and 
measuring of onset time, basic regimes during labour, and the study population, making it 
almost impossible to extrapolate results between studies (113). Lignocaine-adrenaline 
mixture without sodium bicarbonate has not shown this advantage in faster onset compared 
with bupivacaine. For a period lignocaine 2% for epidural use was not available in Sweden 
and we then changed to ropivacaine 0.75%, used in study V. Ropivacaine 0.75%, 
levobupivacaine 0.5%, and lignocaine-adrenaline-fentanyl mixture was compared by Sng et 
al. as top up of labour epidural, during labour maintained with ropivacaine 0.1% and fentanyl 
2 µg/ml 10 ml/h, for urgent CS, and no significant difference was found regarding onset time 
(114). They found median onset time was 10, 10 and 9.5 min respectively, defined “start of 
anaesthesia to ready for surgery”, which is in line with our onset time in study V (114).  
Seven tEDA-CS exceeded the 30 minutes rule with additional 1-11 minutes with the neonatal 
outcome for Apgar at 5 min. 9 for one, and 10 for the other six, and median pHa 7.22 within 
range 7.13-7.29.  
After delivery we routinely add morphine 2 mg in tEDA to prolong postoperative analgesia. 
However we studied only the initial timeframes of the ECS and did not follow the patients 
protracted, with a broader outcome and this is a limitation. Addition of epidural morphine 
was studied and compared with parenteral opioids in elective CS by Bonnet et al. In that 
systematic review they conclude epidural morphine increase quality of analgesia after 
elective CS during the first postoperative day, but with increased side effects, like pruritus 
and nausea and recommend a 4 mg dose of epidural morphine for good pain relief (115). In a 
multimodal concept Singh et al. compared two different doses of epidural morphine, 3 mg 
and 1.5 mg and found similar effect regarding pain and rescue opioid consumption, of 
halving the dose, but reduced side effects (116). Vora et al. studied both onset of analgesia 
and duration after CS, performed in epidural analgesia, by comparing three groups with 
postoperative addition of sufentanil 50 µg, morphine 4 mg or mixture sufentanil 25 µg plus 
morphine 2 mg (117). They found the combination of sufentanil and morphine producing a 
more rapid onset and a longer duration of analgesia, with less side effects, than the either of 
the two drugs alone (117).  
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We found in study III, 12/32 obstetric anaesthesia units supplement with morphine, 
corresponding to 37 % with regard to impact of performed share of CS in Sweden, 10 of 
these units using a 2 mg dose. Sufentanil was the most common lipophilic opioid used in 
epidural anaesthesia for CS, used in 15 units (39%) to compare with fentanyl, used in 10 units 
(25%). Most common dose of sufentanil was 5-10 µg and fentanyl 50-100 µg.  
It is reasonable to believe there are mothers in Sweden that would benefit from receiving a 
dose of epidural morphine 1.5-2 mg to increase quality of analgesia after CS in units not 
using it.  
6.4.3 Emergent CS 
We found a DDI < 30 minutes was achieved in absolute majority of ECS, 92%, and our 
anaesthetic service in line with guidelines 24/7 in study V. This is superior compared to 
findings in 2014 by Tolcher et al.; 79% of category 1 CS and 36% of category 2 CS were 
performed within 30 min. The ten RA CS that exceeded 30 min. in our study, had all good 
neonatal outcomes. GA had the shortest DDI; 10 min., spinal 20 and tEDA 23 min. with no 
significant difference seen between SA and tEDA.  
Unfortunately we collected information only about the conducted anaesthesia in study V, and 
we are not able to conclude the amount of intended, supplemented with analgesics and/or 
failed regional anaesthesia, if any. Change of anaesthesia was not included in protocol though 
it is an important view to control and this is a limitation. If registered, the reason for changing 
anaesthesia may be difficult to truly sort out in the emergent situation, since the maternal or 
foetal situation may deteriorate quickly, or be hard to diagnose, the obstetrician may feel 
distressed by waiting even for few minutes for anaesthesia to be established, though full 
analgesia is expected in short time (41, 118). The role of good communication is central, to 
be prepared and pre-informed, about patients at risk for ECS is best in view of anaesthetists, 
patients and the whole team. Trust and co-operation within the team are most important, 
never overvalued (40, 41, 118).  
The obstetrician decides within what time delivery is needed, and anaesthetist what 
anaesthesia is best to use according to this with regard to the mother. General anaesthesia is 
chosen for the most urgent CS and, not surprisingly, associated with shortest DDI in our 
findings, but in general also conducted with increased risk for the mother; risk of failed 
intubation, aspiration, other respiratory complications, but the risk difference between GA 
and RA has decreased during the years (50, 119, 120). GA during CS is also associated with 
higher risk of persistent pain (2). Epidural and spinal anaesthesia offer the opportunity to add 
low dose of morphine to provide effective postoperative analgesia with long duration superior 
to oral, invasive or local analgesic peripheral methods, but with some increase in side effects 
(17, 24, 39, 115). 
We strive to use GA for ECS only when regional anaesthesia is contraindicated or at those 
indications that really need immediate delivery, which is a much more complicated process 
than it may first appear to the anaesthetist and rest of the team involved (40, 41, 118). For 
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emergent CS where delivery is estimated not immediate but with need within 30 minutes, we 
have worked with the whole process to minimize time-shares and for all included moments 
between decision and delivery; information to anaesthetist, call and gathering of the surgical 
team, transport of patient to OR, start of anaesthesia, time to anaesthesia is established, 
incision (=start of operation) and delivery. To use this time optimally for most important 
actions, get the best quality from this time, is crucial. As described in study V this includes as 
far as it is possible, to have information about patients at risk in advance, and if possible to 
establish a labour epidural as well, and be informed if any problems show up. The 
obstetrician calls and informs the anaesthetist (specialist) directly after decision of ECS, 
including existing labour epidural, and then press the alarm to gather the team to the OR 
especially reserved for ECS. When the team is gathered the obstetrician have a second 
opportunity to decide whether there is need to deliver immediately or within 20-30 minutes, 
often after CTG is controlled. In Table 15 CS indications are listed along with used 
anaesthesia. However the CS indication alone does not give us enough information about 
how urgent the delivery is within the theoretical 30-minute rule. The obstetrician has to, in a 
short time deal with a more complex decision including information about history of CTG, 
lactate tests, the foetal growth and maturity and the mother etc.  
Our data, DDI time and neonatal outcome imply the process of decisions, obstetrical and 
anaesthesia including mutual communication and logistics, is well working. Apgar-score at 5 
min. <7 was more frequently seen among neonates in GA group; 11/64 to compare with 2/30 
in SA group, and 1/41 in tEDAgroup (p<0.05). We also found neonatal pH <7.1 more 
frequently among deliveries having GA than RA; 14/64 compared to 2/30 with SA and 1/41 
having t EDA, all 3 RA with DDI within 30 min. This is an observational study without 
intervention and we interpret the neonatal data associated with anaesthetic technique as the 
fastest anaesthesia; GA is adequately chosen for the most urgent cases with highest foetal 
distress.  This is in line with findings of Blom et al. showing CS performed within 30 minutes 
were associated with more compromised new-borns, and Dunn et al. comparing GA and RA, 
found GA associated with shorter DDI and a worse perinatal outcome (121, 122). 
If indicated the mother receives terbutaline before or after decision, as intrauterine foetal 
resuscitation, but we did not within study V collect information about tocolytics 
administration, which is a limitation. Neither did we analyse number of patients experiencing 
hypotension nor amount of consumed vasopressor.  When the anaesthetist gets information 
about labour epidural in place, topping up is usually started in the delivery room or when 
patient is on its way to OR within short reach, by the anaesthetist, who stay monitoring the 
patient. During the topping up, foetal heart rate monitoring is continued and with improved 
FHR pattern the need of urgency decreases. These are factors that might affect DDI time.  
6.5 INTRATHECAL MORPHINE AND SIDE EFFECTS 
When 100 women are administered 100 µg ITM Dahl et al. assessed number of patients 
experiencing pruritus, vomiting and nausea to be 43, 12 and 10 respectively (93). Bonnet et 
al. found increased incidences of pruritus and nausea after epidural morphine (115). They still 
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recommend use of a 100 µg ITM and a 4 mg dose of epidural morphine respectively to 
provide good pain relief after CS (93, 115). 
In Study III only 20/32 units, corresponding to 61% when assessing the impact of routine 
with regards to the performed CS in those units, were using ITM in Sweden. We find the 
difference in routines in study III surprising, implying there are possibilities to improve peri- 
and postoperative treatment with regard to Carvalho et al. findings about patients preferences 
for anaesthesia outcomes in caesarean delivery where intra- and postoperative pain is most 
feared (86).  
We did not observe difference regarding side effects between groups in study I or II, with 
exception for pruritus, seen only in groups receiving ITM. No patient in any of our studies 
experienced severe adverse event, no respiratory depression needing naloxone, but the studies 
were not powered to detect side effects. Meylan et al. performed a meta-analysis regarding 
ITM benefits and risks and found increased incidence of pruritus [OR 3.85 (95% CI 2.40–
6.15)] and of respiratory depression [odds ratio (OR) 7.86 (95% CI 1.54–40.3)] but with no 
clear linear dose-responsiveness (110). 
6.5.1 Respiratory depression 
From the obstetric anaesthesia units in Sweden withholding morphine in study III, the reason 
was fear of late respiratory depression or problems to monitor, answered by 7/12 units. Risk 
of respiratory depression with morphine, neuroaxial and systemic use, must be acknowledged 
but the risk with use of neuraxial morphine anaesthesia with doses limited to < 200 µg may 
have become excessively emphasised due to doses used in the 80ths. With a dose < 300 µg, 
respiratory depression is proposed not more frequently occurring than with systemic use of 
morphine, but with ITM, rare but more challenging late respiratory depression occurs (24, 
123). Most of the large obstetric units in Sweden have, as in our hospital, implemented 
routines for prolonged monitoring as recommended by SFAI, with the first 2-6 hours either in 
postoperative care or delivery ward, and following hours, up to at least 12 hours, in regular 
maternity ward. Unfortunately we did not ask further questions about routines of pain 
treatment and outcome, but multimodal neuroaxial opioid anaesthesia, including paracetamol 
and NSAID is proven superior to pain treatment models based on oral and intravenous 
morphine, TAP and wound infusion catheters (39, 100). 
In Danderyd hospital we have had the routine for 17 years to administer 100 µg ITM to 
hyperbaric bupivacaine 11-12 mg and 10 µg fentanyl for CS spinal anaesthesia in a multi 
modal concept along with paracetamol and NSAID at a regular base, producing generally 
good pain-relief and few complaints of side effects. To our knowledge there is no known 
severe side effect occurrence, no known case of respiratory depression needing naloxone, 
during these years. Anecdotally midwives reacted surprised and satisfied when the routine 
was introduced and wondered about “the remarkable effect” that made earlier mobilization 
possible and by their judgement, higher maternal satisfaction. Still among obese mothers 
there is a greater risk of post-operative respiratory impairment, which can be aggravated by 
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ITM. We wanted in depth to explore obese mothers the night after morphine spinal CS, and 
whether polygraphy equipment used in OSA-diagnosing would be of help in revealing 
pathologic breathing pattern, not detected by our routine monitoring (10, 43).  
We consider our findings in study IV as normal/mild in this at risk cohort; moderately obese 
mothers postoperatively the night after caesarean section in spinal anaesthesia with 100 µg 
ITM and 10 µg fentanyl. All but 2 mothers showed an AHI well within normal (n=11) and 
mild (n=7) ranges and 2 had values in the lower edge of moderate zone (15.3 and 18.2). No 
mother was found having AHI defined as severe sleep apnoea. Even mild or moderate sleep 
apnea may cause adverse effects, and preoperative screening and testing for sleep apnea in 
accordance with guidelines is recommended, to find women who would gain from treatment 
with continuous positive airway pressure (124). However we found postoperative respiratory 
polygraphy cumbersome and it seems not to provide much critical information. Upper airway 
compromise with obstructive hypo- or apnoea was not frequently seen in this group of 
moderately obese mothers. Mothers with a high AHI did not show typical high oxygen 
desaturation index or TcCO2 elevation. The two devices used showed somewhat different 
AHI ODI correlation. The Nox device showed a correlation between AHI and ODI 0.7 with 
the ODI providing higher indices, the Embletta showed a correlation 0.78 with AHI 
showing higher indices. We are not able to further in depth assess these differences. It may 
be regarded as a limitation that we used different polygraphic equipment, during the study. 
The Embletta was used routinely in sleep apnoea screening in our department at the time of 
start of study IV but was changed to Nox after first eight patients were examined. We found 
the Nox smaller and easier for the mothers to cope with, and we assessed it provided 
information as good as that of the Embletta.  
Short episodes of oxygen desaturation were observed, but whether these events were related 
to bradypnea, or shallow breathing, we are unfortunately not able to assess. None of the 
mothers showed a transcutaneous carbon dioxide elevation, no registration above 5.9 kPa, 
thus all mothers had normal values of TcCO2. The TcCO2 monitoring was however not set 
for detecting brief episodes of CO2 elevation, since it had a 5-minutes averaging algorithm. 
Respiratory depression is known to progress slowly (24). Also the screening ESS scores were 
low, 3 mothers scored more than 10, commonly assessed as threshold value.  
There are few studies with polygraphy registration sleep apnoea, associated with ITM. The 
effects of 30 mg oral morphine and effects of remifentanil infusion were assessed in different 
studies, on patients with mild to moderate obstructive sleep apnoea and showed paradoxically 
that opioids may improve sleep apnoea, but oxygenation was worsened by remifentanil 
infusion (125, 126). Respiratory effects of 300 µg dose of ITM to patients having orthopaedic 
operations under spinal anaesthesia were studied in a RCT concept and Cole et al. found in 
similarity to us that night time polygraphy is cumbersome, similar incidence of apnoea 
/hypopnea episodes in both groups, but lower mean oxygen saturation in the ITM-group 
(127). Likewise in a Cochrane review, assessing the effects of opioid, hypnotic and sedating 
medications on sleep-disordered breathing in adults with obstructive sleep apnoea, none of 
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the studied drugs produced a significant increase in AHI or ODI and two trials even showed a 
beneficial effect (128). However catastrophic events are described related to obesity, 
undiagnosed sleep apnoea, opioids, sedatives and lack of monitoring (129).  
We found polygraphy as postoperative monitoring after CS of limited value. Monitoring of 
respiratory rate, transcutaneous oxygen and carbon dioxide measure may be more feasible 
(130-132). Oximetry after CS with 150 µg ITM showed frequent mild desaturation events 
and increased risk in patients with obesity (130). Transcutaneous CO2 postoperative 
monitoring after CS with similar dose, 150 µg ITM showed frequent hypercapnia events, 
defined >50 mm Hg for ≥2minutes duration, and higher baselineTcCO2 readings (131). 
Dalchow et al. found Tosca® TcCO2 monitoring after CS detecting respiratory depression (>7 
kPa for >2 min) in a higher incidence compared to desaturation (<90% for >2 min) (132).  
There are several limitations with study IV. We have few registrations, only 20 mothers with 
satisfactory registration. We had difficulties including obese parturients. In our hospital we 
perform about 1100 elective caesarean sections every year. The amount of obese parturients 
in this group is not known but with 8.7% obesity in pregnancy in Stockholm we assume a 
number of 90-100 would be likely every year. Among these obese mothers language 
difficulties are not uncommon; not possible to include. In addition some declined 
participation, understandable in this unique situation, becoming parent. The low incidence of 
obesity also explains the, in terms of obesity relative low BMI (mean 35) in our study and a 
higher BMI and more patients would have been of interest. With the portable polygraphy we 
are not able to assess sleep time or if the mothers were merely resting, that requires full 
polysomnography, but the polygraphy equipment has shown similar diagnostic information 
but may underestimate sleep apnoea severity (133). 
Preoperative assessment for sleep apnea should be performed in at risk patients, eventually 
including polysomnography (134). How to screen for OSA during pregnancy is however not 
well defined. Berlin questionnaire or Epworth sleepiness scale was found poorly predictive of 
OSA among pregnant women and associated with high false referral rate (135). For pregnant 
obese women, especially in case of hypertension and preeclampsia, snoring and/or gestation 
diabetes, that are associated with increased incidence of OSA, assessment seems warranted 
earlier during pregnancy since untreated OSA may affect maternal and foetal outcome (134, 
136, 137). Detecting these women at risk and offering them treatment with continuous 
positive airway pressure, has shown promising results, like decreased hypertension and less 
preeclampsia development (138, 139). This handling would also decrease risk of meeting 
undiagnosed OSA obstetric patients at risk postoperatively.  
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7 CONCLUSIONS 
 
• Intrathecal morphine in doses of 100 µg or less, as supplement to bupivacaine and 
sufentanil spinal analgesia for labour pain, was not found advantageous regarding 
duration, onset of analgesia or impact on following epidural doses. 
• Intrathecal morphine as supplement to bupivacaine, for postoperative pain after 
abdominal hysterectomy, reduces first 24 hours post-operative PCAmorphine 
consumption and pain (VAS). We found additional effect of 200 µg compared to 
100 µg but no advantage from increasing the dose to 300 µg. 
• Intrathecal/epidural morphine, fentanyl and sufentanil use is widely spread in 
Sweden as supplement in spinal anaesthesia for mainly CS and abdominal 
hysterectomy but varying regimes exist. A majority combine lipophilic opioid 
(fentanyl or sufentanil) with rapid onset with hydrophilic, long-acting morphine, but 
some anaesthesia units use solely lipophilic opioid and some use only hydrophilic 
morphine as adjunct to local anaesthesia.  
• Risk for respiratory depression and difficulties in monitoring are still considered 
main reasons for restricting use of intrathecal/epidural morphine in some units in 
Sweden. 
• Postoperatively during the night after caesarean section in spinal anaesthesia 
including low dose intrathecal morphine, short episodes of mild oxygen saturation 
decrease were observed in moderately obese mothers, but upper airway collapse, 
obstructive hypo- or apnoea – high AHI - was not found.  
• We found sparse clinical benefit in using portable polygraphy as postoperative 
respiratory monitoring in obese mothers first night after caesarean section in spinal 
anaesthesia with low dose intrathecal morphine.  
• We found spinal anaesthesia with bupivacaine, morphine and fentanyl mixture, as 
well as top-up labour epidural provided similar rapid time to delivery and seem a 
reasonable benefit vs. risk option for category 1 and 2 ECS with acceptable DDI 
within 20–30 minutes.  
• We found no reason to exclude intrathecal morphine in the emergency caesarean 
service. 
• General anaesthesia was, as expected, associated with a more rapid DDI, 10-13 
minutes faster vs. spinal and top up epidural respectively, with no difference 
observed between RA-methods. 
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8 FUTURE PERSPECTIVE 
 
• RCT: Intrathecal addition of morphine 100 µg to patients’ postpartum revision 
operations after maternal vaginal traumatic births. Observe differences regarding 
occurrence of acute and persistent pain. 
 
• RCT: Before removing the epidural catheter add 2 mg of morphine to mothers 
having had vaginal birth. Observe differences regarding occurrence of acute and 
persistent pain. 
 
• RCT: Laparoscopic robotic gynaecologic surgery including hysterectomy – addition 
of 0, 100, or 200 µg of ITM.  Observe differences regarding occurrence of acute and 
persistent pain, postoperative morphine consumption, mobilization and hospital stay 
and persistent pain.  
 
• Observation of pain after CS, a prospective study, elective and emergent CS, with 
respect to acute and persistent pain, indication, different anaesthesia, postoperative 
analgesia, pain before CS, surgical approach, time of day and neonatal outcome.  
 
• Observation study/ RCT, including women during pregnancy, with BMI > 30, with 
hypertension, snoring and/or gestational diabetes. Screening use of polygraphy 
registration during sleep and CPAP treatment if positive findings. Follow through 
pregnancy – outcome – maternal, foetal and CS rate? Postoperative complications?  
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Bakgrund: Smärta är ett kliniskt problem i samband med förlossning och postoperativt efter 
kejsarsnitt och operationer där livmodern opereras bort. Det finns flera anledningar, både 
humana och ekonomiska till att minimera smärtan då smärtan med minskat välbefinnande, 
påverkar hela förlossningsupplevelsen och det postoperativa förloppet, och förlänger 
vårdtiden på sjukhus. Otillräcklig smärtbehandling är en riskfaktor för långvariga 
smärttillstånd (1, 3). Multimodal smärtbehandling, där man kombinerar olika läkemedel med 
olika mekanismer för att nå adderad eller synergi effekt som minimerar både smärta och 
också biverkningar är idag rekommenderad praxis (16). Användandet av låg dos morfin i 
ryggbedövning kan ge god smärtlindring med långvarig effekt, men användningen begränsas 
av biverkningar där risk för försämrad andning är den mest fruktade (34, 38, 76). Fetma, 
övervikt medför ökad risk för påverkan på andningen, nedsatt andning och ökad risk för s.k. 
sömnapné. Fetma ökar också risken för andningsdepression av morfinpreparat, vilket 
sammantaget innebär ökad risk för försämrad andning efter kejsarsnitt där man använt spinal 
bedövning med tillsats av morfin (10).  
Syftet med dessa studier var att undersöka effekterna av en liten dos morfin som tillägg i 
ryggbedövning ur olika aspekter; vid smärtlindring med spinal bedövning under förlossning, i 
spinalbedövning vid livmoderoperation för förbättrad smärtlindring efteråt, kartlägga 
användandet av morfin i ryggbedövning i Sverige, utreda om utrustning som används för 
utredning av sömnapné kan förbättra kunskapen om andningspåverkan hos överviktiga 
mödrar efter kejsarsnitt i ryggbedövning med morfin och slutligen användandet av olika 
anestesimetoder, generell och regional anestesi med morfin vid omedelbara och brådskande 
kejsarsnitt.     
Metoder and Resultat: Studie I and II är randomiserade (= lottade till olika grupper för 
olika behandling) dubbel-blindade (=vare sig undersökare eller patient vet vid 
undersökningen vilken behandling patienten får) placebokontrollerade (= En av 
behandlingsgrupperna får placebo) undersökningar av effekterna av att ge olika doser av 
morfin som tillägg till lokalbedövning i spinalbedövning.  
I Studie I jämförde vi tillägg av morfin 50 eller 100 µg eller placebo till bupivakain (1.25 
mg) och sufentanil (5 µg) för att värdera om morfin förlängde tiden som patienterna var 
smärtlindrade av ryggbedövningen. Nittio först-födande kvinnor i förlossningsarbete fick en 
kombinerad spinal- epidural bedövning och vi bedömde tiden som patienterna var 
smärtlindrade av spinalbedövningen, som tiden från injektionen till smärta återkom i styrka 
enligt VAS > 4.  Vi fann inga skillnader mellan grupperna avseende tid till smärtlindring, tid 
till dess smärta återkom, biverkningar, förlossningsförlopp eller utfall för barnet.  
I Studie II lottades 144 friska kvinnor, som skulle genomgå bortoperation av livmodern i 
kombinerad ryggbedövning och narkos, till fyra grupper där samtliga i spinal fick 
lokalbedövning – bupivakain tung 12 mg kombinerat med 100, 200 och 300 µg morfin eller 
koksalt. Vi undersökte effekten av smärtlindring dygnet efter operationen, genom att 
kontrollera mängden morfin patienten behövde både givet av sköterska och från patientstyrd 
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pump. Morfintillägg i spinalbedövning minskade morfinkonsumtionen postoperativt, 100 µg 
minskade morfinbehovet efter operationen signifikant jämfört med placebo vid 0-6, 6-12 och 
under hela mätperioden 0-24 timmar.  Morfindosen 200 µg minskade signifikant ytterligare 
det intravenösa morfinbehovet jämfört med 100 µg vid 0-6 timmar och för hela mätperioden 
0-24 timmar. Däremot sågs ingen ytterligare skillnad med morfin 300 µg jämfört med 200 
µg. Illamående var lika vanligt i alla grupper. Klåda sågs endast i morfingrupperna. Inga 
allvarliga bieffekter förekom: ingen patient fick försämrad andning.  
I Studie III kartlades hur stor användningen är av morfin och övriga opioider är givet i spinal 
och epidural, till huvudsakligen kejsarsnitt och vid bortoperation av livmodern på sjukhus i 
Sverige. Vi sände en enkät till narkosläkare ansvariga för obstetrisk anestesi vid samtliga 
förlossningssjukhus i Sverige och erhöll svar från 32 av 47 enheterna (68%). Vid kejsarsnitt 
använde 20/32 enheter morfintillägg i spinal med vanligaste dos 100 µg (17/21). Vid 
kejsarsnitt i epidural använde 12/32 kliniker morfintillägg med vanligaste dos 2 mg. Vid 
bortoperation av livmodern använde 20/32 enheter morfin i spinalbedövning och 9/32 
använde 200 µg. Risk för andningsdepression/ svårigheter att övervaka angavs som anledning 
att avstå morfin i ryggbedövning.  
Studie IV är en beskrivande observationsstudie för att undersöka förekomst av sömnapné 
bland överviktiga mödrar postoperativt första natten efter kejsarsnitt i spinalbedövning med 
morfintillägg, och om portabel utrustning för sömnapné kan tillföra kunskap och användas i 
övervakning i denna grupp. Bland de 20 mammor som genomförde andningsregistreringen 
hade 11 (andningsuppehålls index) AHI <5 (normalt); 7, AHI ≥5 - <15 (lätt ökat); och 2, AHI 
≥5 15 (moderat, 15.3 and 18.2). Vi fann inte något samband mellan AHI och ODI 
(syremättnads index) eller tecken på förhöjda koldioxid värden mätt genom huden. Medel 
värdet för ODI var 4.4 (normalt) men åtta mammor hade värden >5. Medel syremättnad var 
94 % (91-96%) och fyra mammor hade medelvärden mellan 91-94% men ingen hade < 90%. 
Ingen av mammorna visade tecken på allvarligt sänkt andningsfunktion i kliniska 
rutinkontroller. Allvarlig påverkan på de övre luftvägarna var inte vanligt förekommande 
första natten efter kejsarsnitt hos mammor med ett BMI >30 som fått 100 µg morfin i 
spinalbedövning tillsammans med 10 µg fentanyl för kejsarsnitt. 
Studie V är en retrospektiv genomgång av akuta larm kejsarsnitt vid Danderyds sjukhus 
under januari – oktober 2016 med syfte att bedöma tiden från beslut om kejsarsnitt till barnet 
är förlöst (DDI) och påverkan av vald anestesi, generell (GA), spinal (SA) med tillägg av 
opoid eller ”top up” av förlossningsepidural (tEDA) med lokalbedövning och fentanyl 
blandning) och arbetsskift. Totalt analyserades 135 kejsarsnitt, 92 % förlöstes inom 30 
minuter och medel DDI var 17.3±8.1 minuter. GA förkortade DDI med 10 minuter och 13 
minuter jämfört med spinal respektive tEDA (p<0.0005). Det var ingen skillnad i DDI för 
spinal och epidural och inte heller beroende på tid på dygnet eller veckodag. Apgar <7 vid 5 
minuter var vanligast vid kejsarsnitt i GA (11 av 64) jämfört med spinal (2/30 och tEDA 
(1/41) (p<0.05). 
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Slutsats: Lågdos morfin i spinal ryggbedövning har en betydelsefull roll för att optimera 
postoperativ smärtlindring i ett koncept för tidig återhämtning efter operation, vid planerade 
och akuta kejsarsnitt och vid bortoperation av livmodern. Morfindoser i spinal ryggbedövning 
över 200 µg förefaller inte ge mer smärtstillande effekt men kan öka risken för biverkningar. 
Om spinalbedövning används som förlossningsbedövning är tillägg av morfin i dos 100 µg 
eller mindre inte meningsfull för att förlänga durationen. Användning av morfin i spinal är 
spridd i Sverige och vanlig framför allt till kejsarsnitt och bortoperation av livmodern men är 
fortfarande begränsad inom vissa enheter, av oro för försvårad andning eller svårigheter att 
övervaka postoperativt. Monitorering av överviktiga mammor (BMI>30) visade inte någon 
mamma med allvarlig sömnapné (OSA) utan generellt normal eller mild påverkan och endast 
två mammor hade apné/hypopné värden (AHI) strax över gränsen till moderat OSA i vårt 
begränsade material. Utrustning för nattregistrering av sömnapné synes vara av begränsat 
värde postoperativt, och inte tillföra något utöver den information som fås av 
andningsfrekvens och transkutan koldioxidmonitorering natten efter kejsarsnitt i spinal med 
tillägg av morfin, men kan behövas göras i ökad omfattning preoperativt eller tidigare under 
graviditeten. De mest akuta kejsarsnitten kunde förlösas inom 30 minuter i 92% och generell 
anestesi förkortade tiden från beslut  till förlossning med 10 och 13 minuter för spinal 
respektive top up epidural bedövning. Ingen tidsskillnad sågs mellan spinal eller epidural 
bedövning eller påverkan av tid på dygnet.
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